US20100010503A1 - Systems and methods for placing heart leads - Google Patents
Systems and methods for placing heart leads Download PDFInfo
- Publication number
- US20100010503A1 US20100010503A1 US12/503,646 US50364609A US2010010503A1 US 20100010503 A1 US20100010503 A1 US 20100010503A1 US 50364609 A US50364609 A US 50364609A US 2010010503 A1 US2010010503 A1 US 2010010503A1
- Authority
- US
- United States
- Prior art keywords
- catheter
- electrodes
- blood vessel
- conductance
- fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 210000002216 heart Anatomy 0.000 title claims description 28
- 239000012530 fluid Substances 0.000 claims description 71
- 238000001514 detection method Methods 0.000 claims description 48
- 210000004204 blood vessel Anatomy 0.000 claims description 40
- 210000003748 coronary sinus Anatomy 0.000 claims description 36
- 230000005284 excitation Effects 0.000 claims description 34
- 210000004369 blood Anatomy 0.000 claims description 29
- 239000008280 blood Substances 0.000 claims description 29
- 210000000056 organ Anatomy 0.000 claims description 14
- 238000012545 processing Methods 0.000 claims description 6
- 210000005245 right atrium Anatomy 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 4
- 210000003191 femoral vein Anatomy 0.000 claims 1
- 230000004807 localization Effects 0.000 abstract description 24
- 210000003484 anatomy Anatomy 0.000 abstract description 11
- 230000003902 lesion Effects 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 59
- 238000002347 injection Methods 0.000 description 41
- 239000007924 injection Substances 0.000 description 41
- 238000005259 measurement Methods 0.000 description 39
- 239000000243 solution Substances 0.000 description 39
- 210000000709 aorta Anatomy 0.000 description 35
- 239000011780 sodium chloride Substances 0.000 description 30
- 238000011282 treatment Methods 0.000 description 29
- 238000013459 approach Methods 0.000 description 28
- 206010002329 Aneurysm Diseases 0.000 description 18
- 208000007474 aortic aneurysm Diseases 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 238000001802 infusion Methods 0.000 description 13
- 208000031481 Pathologic Constriction Diseases 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000002513 implantation Methods 0.000 description 9
- 208000037804 stenosis Diseases 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- 238000009125 cardiac resynchronization therapy Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000036262 stenosis Effects 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 7
- 210000002837 heart atrium Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 210000003492 pulmonary vein Anatomy 0.000 description 7
- 206010007559 Cardiac failure congestive Diseases 0.000 description 6
- 238000002399 angioplasty Methods 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 210000001105 femoral artery Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003090 iliac artery Anatomy 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 210000004115 mitral valve Anatomy 0.000 description 5
- 238000004513 sizing Methods 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000002254 renal artery Anatomy 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 238000011477 surgical intervention Methods 0.000 description 4
- 210000000626 ureter Anatomy 0.000 description 4
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 210000001992 atrioventricular node Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000005246 left atrium Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 0 CCC(C)(C1C(C23CC)*2=C*)C1C3=C Chemical compound CCC(C)(C1C(C23CC)*2=C*)C1C3=C 0.000 description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000005242 cardiac chamber Anatomy 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003673 Atrioventricular block complete Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000001750 Endoleak Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 206010034476 Pericardial haemorrhage Diseases 0.000 description 1
- 244000208734 Pisonia aculeata Species 0.000 description 1
- 208000004717 Ruptured Aneurysm Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010064396 Stent-graft endoleak Diseases 0.000 description 1
- NNEQAKBROMAJTP-UHFFFAOYSA-N [O-][N+](CCN1CC1)=O Chemical compound [O-][N+](CCN1CC1)=O NNEQAKBROMAJTP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 201000002303 hemopericardium Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002608 intravascular ultrasound Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical compound [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 210000003102 pulmonary valve Anatomy 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002931 third-degree atrioventricular block Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000591 tricuspid valve Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0538—Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/0215—Measuring pressure in heart or blood vessels by means inserted into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0223—Operational features of calibration, e.g. protocols for calibrating sensors
Definitions
- Treatment of certain cardiovascular diseases such as aortic aneurysms or chronic heart failure often includes positioning devices within the aorta or the coronary sinus through catheterization. Such procedures require precise placement of the implanted devices within the target lumens, and can result in severe complications if such implantations are inaccurate. Accordingly, having a clear map of the aorta and/or coronary sinus minimizes the risks involved in these procedures.
- An aortic aneurysm is a ballooning of the wall of an artery resulting from the weakening of the artery due to disease, heredity, aging or other conditions.
- disease heredity, aging or other conditions.
- an area of the aortic wall weakens, the pressure of the blood flowing through the weakened area causes the vessel wall to balloon out, forming a blood-filled aneurysm sack.
- aneurysms Although most aneurysms are initially small, aneurysms tend to enlarge over time. Left untreated, the aneurysm will frequently rupture, resulting in loss of blood through the rupture.
- Aortic aneurysms are the most common form of arterial aneurysm and are life threatening due to the massive internal bleeding that results from rupture.
- AAA abdominal aortic aneurysms
- ruptured aneurysms account for more than 15,000 American deaths each year, making the AAA the thirteenth leading cause of death in the United States.
- the aorta is the main artery that carries blood from the heart to the rest of the body.
- the aorta arises from the left ventricle of the heart, extending upward and bending over behind the heart, and thereafter extending downward through the thorax and abdomen.
- the abdominal aorta supplies the two side vessels to the kidneys, the renal arteries.
- Below the level of the renal arteries the abdominal aorta continues to about the level of the fourth lumbar vertebrae where it divides into the iliac arteries.
- the iliac arteries supply blood to the lower extremities and perineal region. Accordingly, the aorta is a major arterial component of the circulatory system and maintaining its general condition is critical to the overall health of the patient.
- AAA is the most common type of aortic aneurysm. Specifically, AAA is an aneurysm that occurs in the portion of the abdominal aorta that is particularly susceptible to weakening between the renal arteries and the iliac arteries. While, in other areas of the aorta the indication that intervention is necessary is when the aneurysm reaches about 5 cm in diameter, an aortic aneurysm larger than about 4 cm in diameter in this section of the aorta is ominous. Left untreated, the AAA may rupture, resulting in rapid and usually fatal hemorrhaging.
- aortic aneurysm Although the mortality rate for an aortic aneurysm is extremely high (about 75-80%), there is also considerable mortality and morbidity associated with surgical intervention to repair an aortic aneurysm. This intervention typically involves going through the abdominal wall to the location of the aneurysm in order to bypass or replace the diseased section of the aorta.
- a prosthetic device typically a synthetic tube, is often used for this purpose.
- the graft serves to exclude the aneurysm from the circulatory system, thus relieving the pressure and stress on the weakened section of the aorta at the aneurysm.
- EVAR treatment involves the placement of an endovascular stent in the aneurismal area of the aorta through a percutaneous technique. Specifically, in most circumstances, the endovascular stent is inserted into a blood vessel (artery or vein), usually through an entry site located in the upper leg or neck. Under fluoroscopy, the stent is navigated through the blood vessels until it reaches the aorta where it is positioned over the aneurysm.
- a blood vessel artery or vein
- EVAR has been reported to have a lower mortality rate as compared to open surgical repair, to effectuate a successful delivery of EVAR, it is necessary to have a clear map of the aorta such that the stent can be properly positioned.
- the aneurysmic regions of the aorta may be quite diseased and atherosclerotic, for the procedure to be successful a healthy portion of the aorta must be present to serve as a landing zone for the stent.
- securing the stent to a diseased region of the aorta will result in a faulty seal that will not adequately reroute the blood flow away from the aneurysmic region, thereby resulting in a reoccurrence of the condition.
- CHF Chronic heart failure
- a patient with acute CHF often experiences sudden shortness of breath, fainting, and irregular heart beats that require frequent emergency room treatments.
- CHF leads to repeated hospital stays, a deterioration in quality of life, and significant costs to the healthcare system.
- SA node sinoatrial node
- AV node atrio-ventricular node
- CRT cardiac resynchronization therapy
- HF moderate to severe heart failure
- Conventional CRT methods employ a pacemaker to pace both ventricles of the heart such that the heart can resynchronize.
- CRT devices have three leads; the first positioned in the atrium, the second positioned in the right ventricle, and the third inserted through the coronary sinus to pace the left ventricle.
- implantation and maintenance of a CRT device are associated with a greater risk than the implantation and maintenance of a standard pacemaker device.
- implantation is compromised by dissection or perforation of the coronary sinus or cardiac vein. Severe complications are associated with the inaccurate implantation of a pacing lead, including complete heart block, hemopericardium, and cardiac arrest (which, together, occurred in about 1.2% of patients).
- cardiac angiography typically involves using a combination of injections of radiocontrast agent or dye and x-ray fluoroscopy to visualize the position and size of blood within the heart. This process, however, is not particularly accurate and does not provide a detailed profile of the coronary sinus.
- a clinician may use embodiments of the devices, systems and methods disclosed herein to accurately identify various bifurcations branching off of the coronary sinus.
- a clinician may further use the embodiments described herein to accurately place a lead within a coronary sinus or a bifurcation branching therefrom.
- a clinician may use embodiments of the devices, systems and methods disclosed herein to create a conductance profile of an aorta that is capable of showing the locations of lesions or other structures. In this manner, conductance profile can be used to accurately treat an aortic aneurysm by employing a stent.
- Some embodiments disclosed herein include systems for localizing a body lumen junction or other intraluminal structure. These systems comprise a catheter having a proximal end and a distal end for placement into a body lumen.
- the catheter may comprise a first electrode and a second electrode, and each of the first and second electrodes have a proximal end and a distal end; the distal ends of the first and second electrodes are located between the proximal and distal ends of the catheter.
- the catheter may comprise a thin wire.
- the system further comprises a processor connected to the first and second electrodes of the catheter. The processor is capable of collecting conductance data to determine a profile of the body lumen.
- the conductance data is collected at a plurality of locations within the body lumen and determined at each of the plurality of locations when the distal ends of the first and second electrodes are immersed in a fluid within the body lumen.
- the processor is also capable of calculating a cross-sectional area of the body lumen at each of the plurality of locations within the body lumen using the conductance data.
- the relevant body lumen comprises at least a portion of an atrium, coronary sinus, aorta, a pulmonary vein-atrial junction, a blood vessel, a biliary tract, or an esophagus. Indeed, many embodiments may be used in connection with any other body lumen that is suitable for access and localization.
- the body lumen may have at least some fluid inside, and the fluid may comprise blood or another suitable fluid, such as a solution of NaCl having a known conductivity.
- Certain embodiments of the catheter have a passageway for passing fluid through the catheter to the location of the distal ends of the first and second electrodes, such that the fluid passing through the passageway comes in contact with the distal ends of the first and second electrodes.
- the conductance data is determined at each of a plurality of locations within the lumen when the distal ends of the first and second electrodes are immersed in a first fluid having a first conductivity and then a second fluid having a second conductivity.
- the conductance data may comprise a first conductance value determined at each of the plurality of locations when the distal ends of the first and second electrodes are immersed in the first fluid and a second conductance value determined at each of the plurality of locations when the distal ends of the first and second electrodes are immersed in the second fluid.
- the profile of the body lumen is therefore determined from the first and second conductance values collected from each of the plurality of locations, the first conductivity of the first fluid, and the second conductivity of the second fluid.
- the profile may consist of actual or relative values for cross-sectional areas or conductances.
- the catheter may comprise a thin wire having at least four electrodes.
- Each of the electrodes has a proximal end and a distal end, wherein the proximal ends of the electrodes may be connected to the processor directly or indirectly.
- the distal ends of the excitation electrodes are located between the proximal and distal ends of the catheter, and the distal ends of the detection electrodes are located between the distal ends of the excitation electrodes.
- Certain embodiments disclosed herein include a number of steps for localizing a junction or other structure within a body lumen, including providing an embodiment of a system as disclosed herein; introducing the catheter into the body lumen; providing electrical current flow to the body lumen through the catheter; measuring a first conductance value at a first location in the body lumen; moving the catheter to a second location in the body lumen; measuring a second conductance value at a second location in the body lumen; and determining a profile of the body lumen based on the first conductance value of the first location and the second conductance value of the second location.
- the profile of the body lumen resulting from such embodiments may include relative conductances and/or relative cross-sectional areas.
- the actual values for the lumen conductance or cross-sectional area are determined by further injecting a known volume of a first solution having a first conductivity into the body lumen; injecting a second solution having a second conductivity into the body lumen, wherein the second solution has a second volume and wherein the second conductivity does not equal the first conductivity; measuring a second conductance value at the first location in the body lumen; calculating the conductance at the first location in the body lumen; measuring a first conductance value at a second location in the body lumen; and calculating the conductance at the second location in the body lumen.
- the determination of the profile of the body lumen may be based on the conductance of the first location, the conductance of the second location, and the conductivities of the first and second solutions.
- the tissue is ablated after localization using the same catheter for both aspects of the procedure.
- FIG. 1 shows the visual output of an embodiment of a catheter system for localization during an experiment of movement through an interior of a surgical glove
- FIG. 2A shows the visual output of an embodiment of a catheter system for localization during an experiment of movement through an interior of a heart
- FIG. 2B shows a mean lumen profile of an aorta as generated by one embodiment of a catheter system for localization
- FIG. 2C shows a mean lumen profile of an aorta generated by one embodiment of a catheter system for localization and further comprising corrections for bifurcations;
- FIG. 3A shows an embodiment of a catheter for localization of a body lumen juncture
- FIG. 3B shows another embodiment of a catheter for localization of a body lumen juncture
- FIG. 3C shows an embodiment of a catheter for localization and ablation of a body lumen juncture
- FIG. 4A shows another embodiment of a catheter for localization
- FIG. 4B shows an embodiment of a balloon catheter having impedance measuring electrodes supported in front of the stenting balloon
- FIG. 4C shows another embodiment of a balloon catheter having impedance measuring electrodes within and in front of the balloon
- FIG. 4D shows an embodiment of a catheter having an ultrasound transducer within and in front of the balloon
- FIG. 4E shows an embodiment of a guide catheter with wire and impedance electrodes
- FIG. 4F shows an embodiment of a catheter with multiple detection electrodes
- FIG. 5A shows an embodiment of a catheter in cross-section proximal to the location of the sensors showing the leads embedded in the material of the probe;
- FIG. 5B shows another embodiment of a catheter in cross-section proximal to the location of the sensors showing the leads run in separate lumens;
- FIG. 6 is a schematic of an embodiment of a system showing a catheter carrying impedance measuring electrodes connected to a data processor equipment and excitation unit for the measurement of conductance and/or cross-sectional area;
- FIG. 7A shows the detected filtered voltage drop as measured in the blood stream before and after injection of 1.5% NaCl solution
- FIG. 7B shows the peak-to-peak envelope of the detected voltage shown in FIG. 7A ;
- FIG. 8A shows the detected filtered voltage drop as measured in the blood stream before and after injection of 0.5% NaCl solution
- FIG. 8B shows the peak-to-peak envelope of the detected voltage shown in FIG. 8A ;
- FIG. 9 shows one embodiment of a catheter for localization being used in the treatment of an aortic aneurysm
- FIG. 10 shows one embodiment of a treatment for an aortic aneurysm
- FIG. 11A shows the voltage recorded by a conductance catheter with a radius of 0.55 mm for various size vessels (vessel radii of 3.1, 2.7, 2.3, 1.9, 1.5 and 0.55 mm for the six curves, respectively) when a 0.5% NaCl bolus is injected into the treatment site; and
- FIG. 11B shows the voltage recorded by a conductance catheter with a radius of 0.55 mm for various size vessels (vessel radii of 3.1, 2.7, 2.3, 1.9, 1.5 and 0.55 mm for the six curves, respectively) when a 1.5% NaCl bolus is injected into the treatment site.
- a stent must be delivered to a disease-free landing zone adjacent to the aneurysm. In the event the stent is inaccurately placed—due to disorientation within the lumen or otherwise—a sufficient seal will not be achieved and the treatment will be ineffective.
- an electrical lead in the treatment of ventricular fibrillation using CRT therapy, an electrical lead must be placed precisely within the coronary sinus through the ostium of the coronary sinus (the junction of the coronary sinus and the right atrium). Achieving the proper placement is an exceptionally difficult procedure, in part because there are various anatomical structures located within the right atrium that can be easily confused with the coronary sinus (e.g., the fossa ovalis, the custaclan ridge, etc.). These particular features of the heart do not show up well on a fluoroscope, therefore making the procedure quite difficult and time consuming for the clinician. Nevertheless, the clinician must be able to accurately insert the catheter into the coronary sinus without perforating the vessel or causing any trauma to the adjacent structures, all while the heart is beating.
- Having a clear map of the coronary sinus in the form of a lumen profile minimizes the risks involved with this procedure and drastically reduces the risk of damaging the surrounding structures. Accordingly, a number of the embodiments disclosed herein permit a clinician to readily locate a catheter, or other medical device, within a body lumen in relation to body lumen junctions or other anatomical structures within the lumen.
- At least one embodiment disclosed herein allows a clinician to accurately measure the luminal cross-sectional area of an organ or body lumen. This leads to proper localization of a targeted tissue, accurate stent sizing and placement, and increased favorable outcomes for certain medical procedures.
- electrical conductance is measured within the body lumen and a profile of relative conductance values is displayed, while other embodiments use conductance data to calculate luminal cross-sectional areas and display a profile of relative cross-sectional areas along a portion of the lumen.
- the disclosed embodiments do not calculate an absolute value for a lumen's cross-sectional area, but instead measure electrical conductance through a portion of the lumen to form a profile of the lumen.
- the profile comprises relative conductances taken along the lumen.
- conductance is proportional to cross-sectional area, as explained herein, the profile can comprise relative cross-sectional areas that have been determined from the conductances taken along the lumen.
- the clinician can visualize the anatomical structure of the lumen. For example, using a push through or a pull back of a disclosed embodiment of a catheter through a lumen, a clinician is able to localize a junction or other architectural marker in the body lumen. Such a push through or pull back technique will reflect, in relative terms, the lumen's changes in conductance, and therefore its changes in cross-sectional area, as the catheter moves, thereby depicting changes in lumen structure across a distance. Based on such changes in lumen structure, a clinician can determine the locations of various anatomical markers of the lumen, as well as the location of the catheter in relation to those markers.
- localization of the junction between an aortic aneurysm and the healthy aortic wall is achieved by assessing the change in conductance (and therefore in cross-sectional area) of the lumen as the catheter is pulled through the aorta and passes the affected tissue.
- the clinician can better treat a targeted tissue at or near that identifying structure.
- Such treatment may include, for example and without limitation, angioplasty or stent delivery.
- a catheter may be inserted into even the smallest blood vessel with a high degree of accuracy (e.g., the coronary sinus).
- FIG. 1 shows the conductance profile 10 as the catheter was pulled back from a finger into the palm of the glove, then was pushed into a finger. As can be seen, the profile shows that the conductance of the palm was significantly larger than the conductance of the finger, and the transition or demarcation from the finger to the palm is apparent.
- conductance profile 10 is proportional to the CSA profile (not shown) and distinguishes between the smaller cross-sectional area of the fingers and the larger cross-sectional area of the palm.
- FIG. 2 shows a conductance tracing 12 that reflects the conductance for each region of the body lumen as the catheter is pulled back over a distance of about 5 cm from a starting point in the pulmonary vein.
- the pulmonary vein can be clearly identified by reference to its relative conductance compared to those of the left atrium, the mitral valve, and the left ventricle.
- the atrial CSA is significantly larger than that of the pulmonary vein, and the atrial CSA increases with distance away from the pulmonary vein-atrial junction.
- a reduction in CSA is then observed as the catheter approaches and crosses the mitral valve. Once the catheter progresses through the mitral valve into the ventricle, the CSA increases gradually.
- a clinician can precisely obtain his or her orientation within the aorta, and thereby localize an aortic aneurysm.
- the various points of bifurcation of the aorta can be identified using the type of conductance data shown in FIG. 2A .
- the conductance data begins to increase, the data indicates that the luminal CSA has increased, especially when such an increase is drastic.
- a conductance or impedance catheter measures conductance within a body lumen using a number of electrodes.
- a conductance catheter 400 configured to localize a body lumen junction using conductance measurements.
- Catheter 400 has a proximal end 405 and a distal end 410 , which is suitable for introduction into a body lumen.
- catheter 400 comprises a thin conductance wire that is capable of accessing the coronary sinus.
- catheter 400 includes a pair of excitation electrodes 415 and a pair of detection electrodes 420 .
- Each of excitation electrodes 415 and detection electrodes 420 has a proximal end that is capable of attachment to a processing system (not shown) and a distal end that is located on catheter 400 between proximal end 405 and distal end 410 .
- the distal ends of detection electrodes 420 are located on catheter 400 between the distal ends of excitation electrodes 415 .
- Excitation electrodes 415 are configured to emit a measured electrical charge into the body lumen, while detection electrodes 420 detect the amount of the charge that travels through a fluid within the body lumen.
- a processing system calculates the change in electrical charge to determine the conductance through the lumen at any given location in the lumen.
- electrodes 415 and 420 are located at distal end 410 of catheter 400 .
- the positioning of the electrodes is not limited to this distal end portion, but may be anywhere on the catheter that can assist in providing conductance information to the clinician.
- multiple sets of electrodes may also be used to provide additional information used for mapping the interior anatomical structure of an internal organ, vessel, or other body lumen.
- Catheter 425 has a proximal end 430 and a distal end 435 , as well as a first electrode 440 and a second electrode 445 .
- Each of electrodes 440 and 445 has a proximal end (not shown) and a distal end located on catheter 425 between proximal end 430 and distal end 435 . Because catheter 425 has only two electrodes, each electrode must serve both the excitation function and the detection function.
- a delay must be added to the circuit.
- a bipolar catheter must be stationary at the time of measurement, requiring the clinician to obtain a profile by moving the catheter to a desired location, stopping and taking a measurement, and then moving the catheter again.
- tetrapolar catheters may take a continuous conductance measurement as the catheter is pulled or pushed through the body lumen, thereby giving a more detailed profile as compared to bipolar catheters.
- infusion passageway 490 is configured to permit such injection so that fluid flowing from passageway 490 will flow at least to the location of the distal ends of excitation electrodes 470 and detection electrodes 480 .
- the fluid passing through passageway 490 into the lumen will come in contact with the distal ends of excitation electrodes 470 and detection electrodes 480 .
- FIGS. 4A to 4F several embodiments of catheters are illustrated.
- an impedance catheter 22 with four electrodes 25 , 26 , 27 , and 28 placed close to distal end 19 of the catheter. Electrodes 25 and 27 are excitation electrodes, while electrodes 26 and 28 are detection electrodes, thereby permitting measurement of conductance (and therefore calculation of cross-sectional area) during advancement of the catheter, as described in further detail below.
- catheter 22 possesses an optional infusion passageway 35 located proximal to excitation electrode 25 , as well as optional ports 36 for suction of contents of the body lumen or for infusion of fluid.
- the fluid to inject through passageway 35 or ports 36 can be any biologically compatible fluid, but, for some circumstances disclosed herein, the conductivity of the fluid is selected to be different from that of blood.
- the catheter contains a channel 31 for insertion of a guide wire to stiffen the flexible catheter during insertion or data recording. Additionally, channel 31 may be used to inject fluid solutions of various concentrations (and various conductivities) into the body lumen of interest.
- An additional channel 32 may be connected to the catheter such that the electrical wires connected to the one or more electrodes on the catheter are directed through channel 32 and to a data processor, such as data processor system 100 (see FIG. 6 ), through an adaptor interface 33 , such as an impedance module plug or the like, as described in more detail below.
- FIGS. 4B-4F show a number of embodiments of conductance catheters having various functions.
- several such embodiments include an angioplasty balloon, in addition to impedance electrodes (see, e.g., FIG. 4B ).
- Such catheters may include electrodes for accurate detection of organ luminal cross-sectional area and ports for pressure gradient measurements.
- the catheter can provide direct measurement of the non-stenosed area of the lumen, thereby allowing the selection of an appropriately sized stent for implantation.
- catheter 20 has a proximal end and a distal end 19 , as well as excitation electrodes 25 , 27 and detection electrodes 26 , 28 placed at or near distal end 19 .
- Proximal to these electrodes is an angioplasty or stenting balloon 30 capable of being used to treat stenosis.
- the distance between the balloon and the electrodes is usually small, in the 0.5 mm to 2 cm range, but can be closer or farther away, depending on the particular application or treatment involved.
- the portion of catheter 20 within balloon 30 includes an infusion passageway 35 and a pressure port 36 .
- Detection electrodes 26 and 28 are spaced 1 mm apart, while excitation electrodes 25 and 27 are spaced 4 mm to 5 mm from either side of the detection electrodes.
- the excitation and detection electrodes typically surround the catheter as ring electrodes, but they may also be point electrodes or have other suitable configurations. These electrodes may be made of any conductive material, such as platinum iridium or a material with a carbon-coated surface to avoid fibrin deposits.
- the detection electrodes are spaced with 0.5 mm to 1 mm between them and with a distance of between 4 mm and 7 mm to the excitation electrodes on small catheters. On large catheters, for use in larger vessels and other larger body lumens, the electrode distances may be larger.
- the dimensions of the catheter selected for a treatment depend on the size of the vessel or other body lumen and are preferably determined in part on the results of finite element analysis.
- dimensions of a catheter to be used for any given application depend on the optimization of the potential field using finite element analysis described below.
- the diameter of the catheter may be as small as 0.3 mm. In large organs, the diameter may be significantly larger depending on the results of the optimization based on finite element analysis.
- the balloon will typically be sized according to the preferred dimension of the organ after the distension.
- the balloon may be made of materials suitable for the function, such as, for example, polyethylene, latex, polyestherurethane, or combinations thereof. In at least one embodiment, the balloon comprises a thickness of a few microns.
- the catheter may comprise PVC or polyethylene material, although other materials may be used equally well.
- the tip of the catheter can be straight, curved, or angled to facilitate insertion into the coronary arteries or other body lumens, such as, for example, the biliary tract.
- catheter 20 may also include several miniature pressure transducers (not shown) carried by the catheter or pressure ports for determining the pressure gradient proximal to the site where the conductance is measured.
- the pressure is preferably measured inside the balloon and proximal to, distal to, and at the location of the conductance measurement, and locations proximal and distal thereto, thereby enabling the measurement of pressure recordings at the site of stenosis and also the measurement of pressure-difference along or near the stenosis.
- catheter 20 includes pressure port 90 and pressure port 91 proximal to or at the site of the conductance measurement for evaluation of pressure gradients. As described below with reference to FIGS.
- the pressure ports are connected by respective conduits in catheter 20 to pressure sensors in the data processor system 100 (see FIG. 6 ).
- pressure sensors are well known in the art and include, for example, fiber-optic systems, miniature strain gauges, and perfused low-compliance manometry.
- a fluid-filled silastic pressure-monitoring catheter is connected to a pressure transducer.
- Luminal pressure can be monitored by a low compliance external pressure transducer coupled to the infusion channel of the catheter.
- Pressure transducer calibration was carried out by applying 0 and 100 mmHg of pressure by means of a hydrostatic column.
- a catheter 39 includes another set of excitation electrodes 40 , 41 and detection electrodes 42 , 43 located inside the angioplastic or stenting balloon 30 for accurate determination of the balloon cross-sectional area during angioplasty or stent deployment. These electrodes are in addition to electrodes 25 , 26 , 27 , and 28 .
- the conductance may be measured using a two-electrode system (see FIG. 4D ).
- the conductances at several locations can be measured at the same time using an array of five or more electrodes.
- excitation electrodes 51 , 52 are used to generate the current while detection electrodes 53 , 54 , 55 , 56 , and 57 are used to detect the current at their respective sites.
- catheter 21 has one or more imaging or recording devices, such as, for example, ultrasound transducers 50 for cross-sectional area and wall thickness measurements. As shown, transducers 50 are located near distal end 19 of catheter 21 .
- electrodes 25 , 26 , 27 , and 28 are built onto a wire 18 , such as, for example, a pressure wire, and inserted through a guide catheter 23 , where the infusion of a bolus can be made through the lumen of the guide catheter.
- Adaptor interface 33 may be used to house and guide the electrical wires (including proximal portions of the excitation and detection electrodes) to a data processor system 100 , while a side channel 34 is used to inject various fluids into catheter 23 .
- the catheter includes a sensor for measurement of the flow of fluid in the body lumen.
- the excitation and detection electrodes are electrically connected to electrically conductive leads in the catheter for connecting the electrodes to the data processor system 100 .
- FIGS. 5A and 5B illustrate cross-sectional views of two embodiments 20 A and 20 B of a catheter such as catheter 20 shown in FIG. 4B .
- Each embodiment has a lumen 60 for inflating and deflating the balloon and a lumen 61 for suction and infusion. The sizes of these lumens can vary.
- the electrode leads 70 A are embedded in the material of the catheter in the embodiment shown in FIG. 5A , whereas the electrode leads 70 B are tunneled through a lumen 71 formed within the body of catheter 20 B shown in FIG. 5B .
- Pressure conduits for perfusion manometry connect pressure ports 90 , 91 to transducers included in the data processor system 100 .
- pressure conduits 95 A may be formed in catheter 20 A.
- pressure conduits 95 B constitute individual conduits within a tunnel 96 formed in catheter 20 B.
- electrical conductors may be substituted for these pressure conduits.
- catheter 20 connects to a data processor system 100 , to a manual or automatic system 105 for distension of the balloon, and to a system 106 for infusion of fluid or suction of blood or other bodily fluid.
- the fluid for infusion may be heated with heating unit 107 to between 37° C. and 39° C. or to body temperature.
- the impedance planimetry system typically includes a constant current unit, amplifiers, and signal conditioners, but variations are possible.
- the pressure system typically includes amplifiers and signal conditioners.
- the system can optionally contain signal conditioning equipment for recording of fluid flow in the body lumen.
- the system is pre-calibrated and a catheter is available in a package.
- the package also may contain sterile syringes with fluids to be injected.
- the syringes are attached to the machine, and after heating of the fluid by the machine and placement of the catheter in the body lumen of interest, the user presses a button that initiates the injection with subsequent computation of the desired parameters.
- the CSA, parallel conductance, and/or other relevant measures, such as distensibility, tension, etc., will typically appear on the display panel in the PC module 160 . The user can then treat the aortic aneurysm by placement of a stent.
- the system can contain a multiplexer unit or a switch between CSA channels.
- each CSA measurement or pressure measurement will be through separate amplifier units.
- the impedance and pressure data are analog signals which are converted by analog-to-digital converters 150 and transmitted to a computer 160 for on-line display, on-line analysis, and storage. In other embodiments, all data handling is done on an entirely analog basis.
- the processor system includes software programs for analyzing the conductance data. Additional software calculates cross-sectional areas based on a number of categories of data, as disclosed herein. However, as discussed in more detail below, to calculate for absolute cross-sectional values, certain errors must be reduced or eliminated.
- the software can be used to reduce the error in CSA values due to conductance of current in the lumen wall and surrounding tissue and to display the two-dimensional or three-dimensional geometry of the CSA distribution along the length of the vessel (and, optionally, along with the pressure gradient).
- a finite element approach or a finite difference approach is used to derive the CSA of organ stenosis, taking parameters such as conductivities of the fluid in the lumen and of the lumen wall and surrounding tissue into consideration.
- the software contains the code for reducing the error in luminal CSA measurement by analyzing signals during interventions, such as infusion of a fluid into the lumen or by changing the amplitude or frequency of the current from the current amplifier.
- the software chosen for a particular application may allow for computation of the CSA with only a small error instantly or within acceptable time during the medical procedure.
- catheter 22 measures conductance in the body lumen by detecting the change in voltage between detection electrodes 26 , 28 , as shown by the following equation:
- the change in voltage, ⁇ V is equal to the magnitude of the current, I, multiplied by the distance between the detection electrodes, L, divided by the conductivity of the fluid in the lumen, C, and divided by the cross-sectional area, CSA. Because the current (I), the distance (L), and the conductivity (C) normally can be regarded as calibration constants during a localization procedure, an inversely proportional relationship exists between the voltage difference and the CSA, as shown by the following equation:
- This measurement does not produce accurate, or absolute, values of conductance or CSA because the wall of the lumen and surrounding tissue effectuate a loss of current.
- the measured conductance over estimates the segment area. This error is related to the dimension of the bifurcation and the angle of the branch, with an angle of 90° resulting in the largest error.
- the amplitude of the conductance is related to the size of the aortic branches; for example, the conductance spike (increase in conductance) resulting from the thoracic branches is smaller than the conductance spike formed when the catheter is pulled past the abdominal branches.
- At least some of the disclosed embodiments overcome the problems associated with determination of the size (cross-sectional area) of luminal organs, such as, for example, in the coronary arteries, carotid, femoral, renal and iliac arteries, aorta, gastrointestinal tract, urethra, and ureter.
- at least some embodiments also provide methods for registration of acute changes in wall conductance, such as, for example, due to edema or acute damage to the tissue, and for detection of muscle spasms/contractions.
- catheter 20 shown in FIG. 4B , is as follows: for electrodes 25 , 26 , 27 , 28 , conductance of current flow through the organ lumen and organ wall and surrounding tissue is parallel; i.e.,
- G ⁇ ( z , t ) CSA ⁇ ( z , t ) ⁇ C b L + G p ⁇ ( z , t ) [ 2 ⁇ a ]
- G p (z,t) is the effective conductance of the structure outside the bodily fluid (organ wall and surrounding tissue);
- C b is the specific electrical conductivity of the bodily fluid, which for blood generally depends on the temperature, hematocrit, and orientation and deformation of blood cells; and
- L is the distance between the detection electrodes.
- Equation [2a] can be rearranged to solve for cross-sectional area CSA(z,t), with a correction factor, a, if the electric field is non-homogeneous, as
- ⁇ would be equal to 1 if the field were completely homogeneous.
- the parallel conductance, G p is an offset error that results from current leakage. G p would equal 0 if all of the current were confined to the blood and hence would correspond to the cylindrical model given by Equation [1a].
- finite element analysis is used to properly design the spacing between detection and excitation electrodes relative to the dimensions of the body lumen to provide a nearly homogenous field such that cc can be considered equal to 1.
- Simulations show that a homogenous or substantially homogenous field is provided by (1) the placement of detection electrodes substantially equidistant from the excitation electrodes and (2) maintaining the distance between the detection and excitation electrodes substantially comparable to the body lumen diameter.
- a homogeneous field is achieved by taking steps (1) and/or (2) described above so that a equals 1 in the foregoing analysis.
- G p is a constant at any given position, z, along the long axis of a body lumen, and at any given time, t, in the cardiac cycle.
- C k For each injection k, C k gives rise to G k which is measured as the ratio of the root mean square of the current divided by the root mean square of the voltage.
- the C k is typically determined through in vitro calibration for the various NaCl concentrations.
- the concentration of NaCl used is typically on the order of 0.45% to 1.8%.
- the volume of NaCl solution is typically about 5 ml, but the amount of solution should be sufficient to momentarily displace the entire local vascular blood volume or other body lumen fluid.
- CSA(t) and G p (t) can be determined at end-diastole or end-systole (i.e., the minimum and maximum values) or the mean thereof.
- the value of CSA would vary through the cardiac cycle, but G p (t) does not vary significantly.
- Equation [2a] allows the calculation of the specific electrical conductivity of bodily fluid in the presence of fluid flow as
- Equation [2b] can be used to calculate the CSA continuously (temporal variation, as for example through the cardiac cycle) in the presence of bodily fluid.
- Equation [2a] can be expressed as
- Equation [8] For the two injections, denoted by subscript “1” and subscript “2”, respectively, different time points T 1 , T 2 , etc. may be considered such that Equation [8] can be written as
- CSA 1 ⁇ ( U ⁇ T 1 , t ) L C 1 ⁇ [ G 1 ⁇ ( U ⁇ T 1 , t ) - G p ⁇ ⁇ 1 ⁇ ( U ⁇ T 1 , t ) ] [ 9 ⁇ a ]
- CSA 1 ⁇ ( U ⁇ T 1 , t ) L C 2 ⁇ [ G 2 ⁇ ( U ⁇ T 1 , t ) - G p ⁇ ⁇ 1 ⁇ ( U ⁇ T 1 , t ) ] ⁇ ⁇ and [ 9 ⁇ b ]
- CSA 2 ⁇ ( U ⁇ T 2 , t ) L C 1 ⁇ [ G 1 ⁇ ( U ⁇ T 2 , t ) - G p ⁇ ⁇ 2 ⁇ ( U ⁇ T 2 , t ) ] [ 10 ⁇ a ]
- CSA 2 ⁇ ( U ⁇ T 2 , t ) L C 2 ⁇ [ G
- Equations [9a], [9b] and [10a], [10b], etc. can be solved for CSA 1 p 1 and CSA 2 , G p2 , respectively.
- the data on the CSA and parallel conductance as a function of longitudinal position along the body lumen can be exported from an electronic spreadsheet, such as, for example, a Microsoft Excel file, to diagramming software, such as AutoCAD®, where the software uses the coordinates to render a three-dimensional depiction of the lumen on the monitor.
- the pull back reconstruction was made during a long injection where the catheter was pulled back at constant rate by hand.
- the catheter was marked along its length such that the pull back was made at 2 mm/sec.
- the catheter was pulled back about 2 cm.
- the data was continuously measured and analyzed at every two second interval; i.e., at every 4 mm.
- six different measurements of CSA and G p were taken which were used to reconstruct the CSA and G p along the length of the 2 cm segment.
- the wall thickness is determined from the parallel conductance for those body lumens that are surrounded by air or non-conducting tissue. In such cases, the parallel conductance is equal to
- the wall thickness, h can be expressed as
- D is the diameter of the lumen, which can be determined from the circular
- the compliance e.g., ⁇ CSA/ ⁇ AP
- tension e.g., P*r, where P and r are the intraluminal pressure and radius of a cylindrical lumen
- stress e.g., P*r/h, where h is the wall thickness of the cylindrical organ
- strain e.g., (C ⁇ C d )/C d where C is the inner circumference and C d is the circumference in diastole
- wall shear stress e.g., 4 ⁇ Q/r 3 where, ⁇ , Q, and r are the fluid viscosity, flow rate, and radius of the cylindrical lumen for a fully developed flow.
- a catheter is introduced from an exteriorly accessible opening (for example, the mouth, nose, or anus for GI applications, or the mouth or nose for airway applications) into the targeted body lumen.
- an exteriorly accessible opening for example, the mouth, nose, or anus for GI applications, or the mouth or nose for airway applications
- the catheter can be inserted into the lumens in various ways, such as, for example, those used in conventional angioplasty.
- an 18 gauge needle is inserted into the femoral artery followed by an introducer.
- a guide wire is then inserted into the introducer and advanced into the lumen of the femoral artery.
- a 4 or 5 Fr is then inserted into the introducer and advanced into the lumen of the femoral artery.
- conductance catheter is then inserted into the femoral artery via wire, and the wire is subsequently retracted.
- the catheter tip containing the conductance electrodes can then be advanced to the region of interest by use of x-ray (e.g., fluoroscopy).
- x-ray e.g., fluoroscopy
- this methodology is used on small to medium size vessels (e.g., femoral, coronary, carotid, iliac arteries).
- an angioplasty or stent balloon includes impedance electrodes supported by the catheter in front of the balloon. As described herein, these electrodes enable the immediate, or real-time determination of the cross-sectional area of the vessel during the balloon advancement.
- impedance electrodes are located in the center of the balloon in order to deploy the stent to the desired cross-sectional area. Such embodiments and procedures substantially improve the accuracy of stenting and the outcome of such stenting, as well as reduce overall costs.
- error due to the loss of current in the wall of the organ and surrounding tissue is corrected by injection of two solutions of NaCl or other solutions with known conductivities.
- a minimum of two injections with different concentrations of NaCl (and, therefore, different conductivities) are required to solve for the two unknowns, CSA and G p .
- only relative values for conductance or cross-sectional area are necessary, so the injection of two solutions is not necessary.
- three injections will yield three sets of values for CSA and G p (although not necessarily linearly independent), while four injections would yield six sets of values.
- At least two solutions are injected in the targeted vessel or other lumen.
- solutions e.g., 0.5% and 1.5% NaCi solutions
- an infusion rate of approximately 1 ml/s for a five second interval is sufficient to displace the blood volume and results in a local pressure increase of less than 10 mmHg in the coronary artery. This pressure change depends on the injection rate which should be comparable to the lumen flow rate.
- the vessel is under identical or very similar conditions during the two injections. Hence, some variables, such as the infusion rate, bolus temperature, etc., are similar for the two injections.
- a short time interval is to be allowed (1 to 2 minute period) between the two injections to permit the vessel to return to homeostatic state. This can be determined from the baseline conductance as shown in FIGS. 7A , 7 B, 8 A, or 8 B.
- the parallel conductance is preferably the same or very similar during the two injections.
- Dextran, albumin, or another large molecular weight molecule may be added to the NaCl solutions to maintain the colloid osmotic pressure of the solution to reduce or prevent fluid or ion exchange through the vessel wall.
- the NaCl solution is heated to body temperature prior to injection since the conductivity of current is temperature dependent.
- the injected bolus is at room temperature, but a mathematical temperature correction is made since the conductivity is related to temperature in a linear fashion.
- a sheath is inserted through either the femoral artery or the carotid artery in the direction of flow.
- the sheath is inserted through the ascending aorta.
- LAD anterior descending
- a catheter having a diameter of 1.9 mm can be used, as determined from finite element analysis, discussed further below.
- the femoral and coronary arteries where the diameter is typically in the range from 3.5 mm to 4 mm, so a catheter of about 0.8 mm diameter would be appropriate.
- the catheter can be inserted into the femoral, carotid, or LAD artery through a sheath appropriate for the particular treatment. Measurements for all three vessels can be made similarly.
- At least one clinical application of the embodiments of the systems and methods disclosed herein relates to the delivery of pacing leads used in CRT, and, in particular, the delivery of a coronary sinus lead.
- CRT cardiac resonator
- the distal end of the coronary lead is advanced through the superior vena cava, the right atrium, the valve of the coronary sinus, the coronary sinus, and may be further advanced into a coronary vein communicating with the coronary sinus, such as the great cardiac vein. Routing a lead along the desired path to implant the electrode in the desired implantation site can be difficult.
- the catheters and systems disclosed herein can obtain precise measurements of the coronary sinus and related branching blood vessels, to facilitate the navigation of such difficult areas.
- the catheters and systems disclosed herein can obtain an accurate profile of the coronary venous system, including accurate identification of bifurcations along the length of the coronary sinus.
- a conductance catheter comprising a thin wire may be employed for delivering a lead into the coronary sinus or a bifurcation branching therefrom.
- the conductance wire can be pulled through the coronary sinus and used to create a conductance profile thereof.
- a clinician can accurately identify—with a high degree of specificity—the various bifurcations branching from the coronary sinus.
- the clinician can identify the bifurcation of interest and thereafter steer the conductance wire therein.
- the lead can be inserted over the wire and placed within the desired bifurcation.
- This application can be conducted using the larger conductance catheters described herein as well; however, the relatively small diameter of a conductance catheter comprising a wire facilitates navigation through the narrow bifurcations branching from the coronary sinus.
- the conductance catheter was inserted through the sheath for a particular vessel of interest.
- a baseline reading of voltage was continuously recorded.
- Two containers containing 0.5% and 1.5% NaCl were placed in temperature bath and maintained at 37° C.
- a 5 ml to 10 ml injection of 1.5% NaCl was made over a 5 second interval.
- the detection voltage was continuously recorded over a 10 second interval during the 5 second injection.
- Several minutes later, a similar volume of 1.5% NaCl solution was injected at a similar rate.
- the data was again recorded.
- Matlab® was used to analyze the data including filtering with high pass and with low cut off frequency (1200 Hz).
- FIGS. 7A , 7 B, 8 A, and 8 B illustrate voltage measurements in the blood stream in the left carotid artery.
- the data acquisition had a sampling frequency of 75 KHz, with two channels—the current injected and the detected voltage, respectively.
- the current injected has a frequency of 5 KHz, so the voltage detected, modulated in amplitude by the impedance changing through the bolus injection, will have a spectrum in the vicinity of 5 KHz.
- FIG. 7A there is shown a signal processed with a high pass filter with low cut off frequency (1200 Hz).
- the top and bottom portions 200 , 202 show the peak-to-peak envelope detected voltage which is displayed in FIG. 7B .
- the initial 7 seconds correspond to the baseline; i.e., electrodes in the blood stream.
- the next 7 seconds correspond to an injection of hyper-osmotic NaCl solution (1.5% NACI). It can be seen that the voltage is decreased, implying increased conductance (since the injected current is constant).
- FIGS. 8A and 8B show similar data corresponding to 0.5% NaCl solutions.
- the voltage signals are ideal since the difference between the baseline and the injected solution is apparent and systematic. Furthermore, the pulsation of vessel diameter can be seen in the 0.5% and 1.5% NaCl injections ( FIGS. 7A , 7 B and 8 A, 8 B, respectively). This allows determination of the variation of CSA throughout the cardiac cycle as outline above.
- the NaCl solution can be injected by hand or by using a mechanical injector to momentarily displace the entire volume of blood or bodily fluid in the lumen segment of interest.
- a mechanical injector to momentarily displace the entire volume of blood or bodily fluid in the lumen segment of interest.
- the pressure generated by the injection will not only displace the blood in the antegrade direction (in the direction of blood flow) but also in the retrograde direction (by momentarily pushing the blood backwards).
- the NaCl solution will not displace blood as in the vessels but will merely open the organs and create a flow of the fluid.
- sensors monitor and confirm baseline of conductance prior to injection of a second solution into the treatment site.
- the injections described above are preferably repeated at least once to reduce errors associated with the administration of the injections, such as, for example, where the injection does not completely displace the blood or where there is significant mixing with blood.
- any bifurcation(s) (with branching angle near 90°) near the targeted lumen can cause an overestimation of the calculated CSA, thereby resulting in a conductance spike (see FIG. 2B ).
- the catheter should be slightly retracted or advanced and the measurement repeated.
- An additional application with multiple detection electrodes or a pull back or push forward during injection will accomplish the same goal.
- an array of detection electrodes can be used to minimize or eliminate errors that would result from bifurcations or branching in the measurement or treatment site.
- conductance spikes when present can be eliminated or smoothed out through a number or computational processing means, including, without limitation, threshold limits, gradient, interpolation, and smoothing algorithms.
- Threshold limits can be programmed to ignore readings for points where the cross-sectional area is greater than a preset number. Threshold limits are convenient to program; however, using solely threshold limits will not allow for differentiation between bifurcations caused by luminal branches and those caused by conditions such as aneurysms. Accordingly, consideration of the gradient (slope) where a conductance spike would correspond to a large, or possibly infinite, gradient.
- This criterion can be used in conjunction with a smoothing algorithm (e.g., linear interpolation or cubic spline) to distinguish a bifurcation from a pathological condition.
- a smoothing algorithm e.g., linear interpolation or cubic spline
- FIG. 2C the data of FIG. 2B is shown after the conductance spikes have been eliminated using at least one computational processing means. Similar profiles can be generated for the coronary sinus and, as such, the effective and convenient navigation thereof can be achieved.
- the width of the conductance spike (not shown) can represent the approximate size (or diameter) of the bifurcation.
- error due to the eccentric position of the electrode or other imaging device can be reduced by inflation of a balloon on the catheter.
- the inflation of the balloon during measurement will place the electrodes or other imaging device in the center of the vessel away from the wall.
- the inflation of the balloon can be synchronized with the injection of a bolus such that the balloon inflation would immediately precede the bolus injection.
- the CSA predicted by Equation [5] corresponds to the area of the vessel or other lumen external to the catheter (i.e., CSA of vessel minus CSA of catheter). If the conductivity of the NaCl solutions is determined by calibration from Equation [1a] with various tubes of known CSA, then the calibration accounts for the dimension of the catheter and the calculated CSA corresponds to that of the total vessel lumen. In at least one embodiment, the calibration of the CSA measurement system will be performed at 37° C. by applying 100 mmHg in a solid polyphenolenoxide block with holes of known CSA ranging from 7.065 mm 2 (3 mm in diameter) to 1017 mm 2 (36 mm in diameter). However, if the conductivity of the solutions is obtained from a conductivity meter independent of the catheter, then the CSA of the catheter is generally added to the CSA computed from Equation [5] to give the total CSA of the vessel.
- the signals are generally non-stationary, nonlinear, and stochastic.
- Spectrogram the Wavelet's analysis, the Wigner-Ville distribution, the Evolutionary Spectrum, Modal analysis, or the intrinsic model function (“IMF”) method.
- IMF intrinsic model function
- the mean or peak-to-peak values can be systematically determined by the aforementioned signal analysis and used in Equation [5] to compute the CSA.
- the conductivity of the blood is transiently changed by injection of a hypertonic NaCl solution into the pulmonary artery. If the measured total conductance is plotted versus blood conductivity on a graph, the extrapolated conductance at zero conductivity corresponds to the parallel conductance.
- two pressure sensors 36 are placed immediately proximal and distal to (1 mm to 2 mm above and below, respectively) the detection electrodes or sets of detection electrodes (see, e.g., FIGS.
- the pressure readings will then indicate the position of the detection electrode relative to the desired site of measurement (aortic valve: aortic-ventricular pressure; mitral valve: left ventricular-atrial pressure; tricuspid valve: right atrial-ventricular pressure; pulmonary valve: right ventricular-pulmonary pressure).
- aortic valve aortic-ventricular pressure
- mitral valve left ventricular-atrial pressure
- tricuspid valve right atrial-ventricular pressure
- pulmonary valve right ventricular-pulmonary pressure
- the parallel conductance at the site of annulus is generally expected to be small since the annulus consists primarily of collagen, which has low electrical conductivity.
- a pull back or push forward through the heart chamber will show different conductance due to the change in geometry and parallel conductance. This can be established for normal patients, which can then be used to diagnose valvular stenosis.
- the procedures can conveniently be done by swallowing fluids of known conductivities into the esophagus and infusion of fluids of known conductances into the urinary bladder followed by voiding the volume.
- fluids can be swallowed or urine voided followed by measurement of the fluid conductivities from samples of the fluid.
- the latter method can be applied to the ureter where a catheter can be advanced up into the ureter and fluids can be injected from a proximal port on the probe (will also be applicable in the intestines) or urine production can be increased and samples taken distal in the ureter during passage of the bolus or from the urinary bladder.
- a mechanical stimulus is introduced by way of inflating the balloon or by releasing a stent from the catheter, thereby facilitating flow through the stenosed part of the lumen.
- concomitant with measuring the conductance, cross-sectional area, and/or pressure gradient at the treatment site one or more pharmaceutical substances for diagnosis or treatment of stenosis is injected into the treatment site.
- the injected substance can be a smooth muscle agonist or antagonist.
- an inflating fluid is released into the treatment site for release of any stenosis or materials causing stenosis in the lumen or treatment site.
- the methods, systems, and catheters described herein can be applied to any body lumen or treatment site.
- the methods, systems, and catheters described herein can be applied to any one of the following hollow bodily systems: the cardiovascular system including the heart; the digestive system; the respiratory system; the reproductive system; and the urogenital tract.
- Finite Element Analysis In one preferred approach, finite element analysis (“FEA”) is used to verify the validity of Equations [5] and [6]. There are two major considerations for the model definition: geometry and electrical properties. The general equation governing the electric scalar potential distribution, V, is given by Poisson's equation as:
- C, I and ⁇ are the conductivity, the driving current density, and the del operator, respectively.
- the FEA allows for the determination of the nature of the field and its alteration in response to different electrode distances, distances between driving electrodes, wall thicknesses, and wall conductivities.
- the percentage of total current in the lumen of the vessel (% I) can be used as an index of both leakage and field homogeneity.
- the various geometric and electrical material properties can be varied to obtain the optimum design, i.e. minimizing the non-homogeneity of the field.
- the experimental procedure was simulated by injection of the two solutions of NaCl to verify the accuracy of Equation [5]. Finally, the effect of the presence of electrodes and the catheter in the lumen of vessel was assessed.
- the error terms representing the changes in measured conductance due to the attraction of the field to the electrodes and the repulsion of the field from the resistive catheter body were quantified.
- Poisson's equation was solved for the potential field, which takes into account the magnitude of the applied current, the location of the current driving and detection electrodes, and the conductivities and geometrical shapes in the model including the vessel wall and surrounding tissue.
- This analysis suggests that the following conditions are optimal for the cylindrical model: (1) the placement of detection (voltage sensing) electrodes equidistant from the excitation (current driving) electrodes; (2) the distance between the excitation electrodes should be much greater than the distance between the detection electrodes; and (3) the distance between the detection and excitation electrodes is comparable to the vessel diameter, or the diameter of the vessel is small relative to the distance between the driving electrodes.
- the equipotential contours more closely resemble straight lines perpendicular to the axis of the catheter and the voltage drop measured at the wall will be nearly identical to that at the center. Since the curvature of the equipotential contours is inversely related to the homogeneity of the electric field, it is possible to optimize the design to minimize the curvature of the field lines. Consequently, in one approach, one or more of conditions (1)-(3) described above are met to increase the accuracy of the cylindrical model.
- FIGS. 11A and 11B show the detected voltage for a catheter with a radius of 0.55 mm for two different NaCl solutions (0.5% and 1.5%, respectively). The origin corresponds to the center of the catheter.
- the first vertical line 220 represents the inner part of the electrode which is wrapped around the catheter, and the second vertical line 221 is the outer part of the electrode in contact with the solution (diameter of electrode is approximately 0.25 mm).
- the six different curves, top to bottom, correspond to six different vessels with radii of 3.1 mm, 2.7 mm, 2.3 mm, 1.9 mm, 1.5 mm, and 0.55 mm, respectively. It can be seen that a “hill” 220 , 221 occurs at the detection electrodes, followed by a fairly uniform plateau in the vessel lumen, followed by an exponential decay into the surrounding tissue. Since the potential difference is measured at the detection electrode 220 , 221 , the simulation generates the “hill” whose value corresponds to the equivalent potential in the vessel as used in Equation [5]. Thus, for each catheter size, the dimension of the vessel was varied such that Equation [5] was exactly satisfied.
- the optimum catheter size for a given vessel diameter was obtained such that the distributive model satisfies the lumped equations (Equations [5] and [6]). In this way, a relationship between vessel diameter and catheter diameter can be generated such that the error in the CSA determination is less than 5%.
- different diameter catheters are prepackaged and labeled for optimal use in certain size vessel. For example, for vessel dimensions in the range of 4 mm to 5 mm, 5 mm to 7 mm, or 7 mm to 10 mm, analysis shows that optimum diameter catheters will be in the range of 0.9 mm to 1.4 mm, 1.4 mm to 2 mm, or 2 mm to 4.6 mm, respectively. The clinician can select the appropriate diameter catheter based on the estimated vessel diameter of interest. This decision will be made prior to the procedure and will serve to minimize the error in the determination of lumen CSA.
- a number of the embodiments disclosed herein accurately calculate lumen cross-sectional area by measuring conductance and correcting for various errors inherent in such measurements.
- at least some of the disclosed embodiments provide for the localization of body lumen junctions and other intraluminal anatomical structures using relative conductances and/or cross-sectional areas. Because only relative differences in conductance or cross-sectional area are necessary for accurate localization, the calculation of absolute values for various locations within the body lumen may be skipped in most instances.
- catheter 22 comprising stent 160 is positioned within an aorta 140 for the treatment of an aortic aneurysm 145 .
- a set of excitation electrodes 25 , 27 , and detection electrodes 26 , 28 are located on catheter 22 , which is disposed within stent 160 .
- catheter 22 and thereby stent 160 , is introduced into the blood stream percutaneously with a femoral approach.
- electrodes 25 , 26 , 27 ,. 28 are activated and electrical current flow is provided to the aortic lumen through the catheter 22 as previously described herein.
- the catheter 22 may release fluid, such as a solution of NaCl having a known conductivity, into the aortic lumen, such that the fluid passing through the lumen comes into contact with the distal end of the electrodes 25 , 26 , 27 , 28 .
- Conductance data is collected at a plurality of locations throughout the aorta 140 to determine a profile and cross-sectional area at various points along the aortic lumen. Further, any inherent errors in collected data can be corrected using any of the computational processes disclosed herein. In this manner, precise cross-sectional values of the aortic lumen can be obtained, as well as an accurate profile map of the region. Based on that data, the aneurysm can be precisely located within the aorta (e.g., where a larger conductance value is detected), and the stent 160 may be properly sized to affix to the aortic wall both distally and proximally of the aneurysm.
- a balloon 30 is used to distend stent 160 within the aneurytic region of the aorta 140 .
- Inflation of the balloon 30 applies a force to the stent 160 which extends radially and presses into the vessel wall just above and just below the aneurysm.
- the profile and cross-sectional area of the aorta determined from the conductance data can be used to identify the optimal diameter to which the balloon 30 should be inflated. Accordingly, the stent 160 can be accurately sized to effectively treat the aneurysm.
- the profile and cross-sectional area of the aorta determined from the conductance data can be used to identify a good landing zone for the deployment of the graft and thus prevent graft migration or endoleak.
- the disclosure may have presented a method and/or process as a particular sequence of steps.
- the method or process should not be limited to the particular sequence of steps described.
- other sequences of steps may be possible. Therefore, the particular order of the steps disclosed herein should not be construed as limitations on the claims.
- the claims directed to a method and/or process should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the sequences may be varied and still remain within the spirit and scope of the present disclosure.
Abstract
Devices, systems, and methods for the localization of body lumen junctions and other intraluminal structure are disclosed. Various embodiments permit clinicians to identify and locate lesions and/or anatomical structures within a lumen and accurately place leads and/or devices within a lumen, through determining the intralumen conductance and/or cross-sectional area at a plurality of locations within the body lumen.
Description
- The present application is a continuation patent application that is related to, and claims the priority benefit of, U.S. patent application Ser. No. 12/503,341, filed Jul. 15, 2009, which is a continuation patent application that is related to, and claims the priority benefit of, U.S. patent application Ser. No. 12/522,432, filed Jul. 8, 2009, which is related to, claims the priority benefit of, and is a U.S. national stage patent application of International Patent Application Serial No. PCT/US2008/000833, filed Jan. 23, 2008, which is related to and claims the priority benefit of: (I) U.S. Provisional Patent Application Ser. No. 60/881,840, filed Jan. 23, 2007; and (2) International Patent Application Serial No. PCT/US2007/015239, filed Jun. 29, 2007, which (a) claims priority to U.S. Provisional Patent Application Ser. No. 60/817,422, filed Jun. 30, 2006; (b) claims priority to and is a continuation-in-part of U.S. patent application Ser. No. 10/782,149, filed Feb. 19, 2004, which claims priority to U.S. Provisional Patent Application Ser. No. 60/449,266, filed Feb. 21, 2003, U.S. Provisional Patent Application Ser. No. 60/493,145, filed Aug. 7, 2003, and U.S. Provisional Patent Application Ser. No. 60/502,139, filed Sep. 11, 2003; and (c) claims priority to and is a continuation-in-part of U.S. patent application Ser. No. 11/063,836, filed Feb. 23, 2005, which claims priority to U.S. patent application Ser. No. 10/782,149, filed Feb. 19, 2004. The contents of each of these applications are hereby incorporated by reference in their entirety into this disclosure.
- Treatment of certain cardiovascular diseases such as aortic aneurysms or chronic heart failure often includes positioning devices within the aorta or the coronary sinus through catheterization. Such procedures require precise placement of the implanted devices within the target lumens, and can result in severe complications if such implantations are inaccurate. Accordingly, having a clear map of the aorta and/or coronary sinus minimizes the risks involved in these procedures.
- An aortic aneurysm is a ballooning of the wall of an artery resulting from the weakening of the artery due to disease, heredity, aging or other conditions. When an area of the aortic wall weakens, the pressure of the blood flowing through the weakened area causes the vessel wall to balloon out, forming a blood-filled aneurysm sack. Although most aneurysms are initially small, aneurysms tend to enlarge over time. Left untreated, the aneurysm will frequently rupture, resulting in loss of blood through the rupture.
- Aortic aneurysms are the most common form of arterial aneurysm and are life threatening due to the massive internal bleeding that results from rupture. In the past 30 years, the occurrence of abdominal aortic aneurysms (“AAA”), in particular, has increased threefold. According to the Society of Vascular Surgeons, ruptured aneurysms account for more than 15,000 American deaths each year, making the AAA the thirteenth leading cause of death in the United States.
- The aorta is the main artery that carries blood from the heart to the rest of the body. The aorta arises from the left ventricle of the heart, extending upward and bending over behind the heart, and thereafter extending downward through the thorax and abdomen. The abdominal aorta supplies the two side vessels to the kidneys, the renal arteries. Below the level of the renal arteries, the abdominal aorta continues to about the level of the fourth lumbar vertebrae where it divides into the iliac arteries. The iliac arteries supply blood to the lower extremities and perineal region. Accordingly, the aorta is a major arterial component of the circulatory system and maintaining its general condition is critical to the overall health of the patient.
- AAA is the most common type of aortic aneurysm. Specifically, AAA is an aneurysm that occurs in the portion of the abdominal aorta that is particularly susceptible to weakening between the renal arteries and the iliac arteries. While, in other areas of the aorta the indication that intervention is necessary is when the aneurysm reaches about 5 cm in diameter, an aortic aneurysm larger than about 4 cm in diameter in this section of the aorta is ominous. Left untreated, the AAA may rupture, resulting in rapid and usually fatal hemorrhaging.
- Although the mortality rate for an aortic aneurysm is extremely high (about 75-80%), there is also considerable mortality and morbidity associated with surgical intervention to repair an aortic aneurysm. This intervention typically involves going through the abdominal wall to the location of the aneurysm in order to bypass or replace the diseased section of the aorta. A prosthetic device, typically a synthetic tube, is often used for this purpose. The graft serves to exclude the aneurysm from the circulatory system, thus relieving the pressure and stress on the weakened section of the aorta at the aneurysm.
- Repair of an aortic aneurysm by surgical means is a major operative procedure. In addition, substantial morbidity accompanies the procedure, resulting in a protracted recovery period. Finally, the procedure entails a substantial risk of mortality. While surgical intervention may be required in spite of these risks, certain patients may not be able to tolerate the stress of intra-abdominal surgery. It is desirable to reduce the mortality and morbidity associated with intra-abdominal surgical intervention.
- In recent years, methods have been developed to attempt to treat an aortic aneurysm without the attendant risks of surgical intervention. One such minimally invasive alternative is endovascular aneurysm repair (“EVAR”). EVAR treatment involves the placement of an endovascular stent in the aneurismal area of the aorta through a percutaneous technique. Specifically, in most circumstances, the endovascular stent is inserted into a blood vessel (artery or vein), usually through an entry site located in the upper leg or neck. Under fluoroscopy, the stent is navigated through the blood vessels until it reaches the aorta where it is positioned over the aneurysm.
- While EVAR has been reported to have a lower mortality rate as compared to open surgical repair, to effectuate a successful delivery of EVAR, it is necessary to have a clear map of the aorta such that the stent can be properly positioned. Although the aneurysmic regions of the aorta may be quite diseased and atherosclerotic, for the procedure to be successful a healthy portion of the aorta must be present to serve as a landing zone for the stent. For example, securing the stent to a diseased region of the aorta will result in a faulty seal that will not adequately reroute the blood flow away from the aneurysmic region, thereby resulting in a reoccurrence of the condition. As accurate placement of the stent is critical, visualization of the aortic structure has been an obstacle for proper navigation during delivery of the stent. Currently, clinicians perform magnetic resonance imaging prior to delivering the stent in order to supply an axial profile of the aorta. However, magnetic resonance imaging is expensive and time consuming to obtain, and the results exhibit limited spatial resolution.
- Chronic heart failure (“CHF”) is another cardiovascular disease, the treatment of which often includes catheterization. CHF is a disease condition in which the heart fails to function efficiently as a pump and cannot provide sufficient blood flow and/or pressure to satisfy the normal circulatory needs of a patient. A patient with acute CHF often experiences sudden shortness of breath, fainting, and irregular heart beats that require frequent emergency room treatments. In its chronic form, CHF leads to repeated hospital stays, a deterioration in quality of life, and significant costs to the healthcare system.
- In about 30% of CHF patients, the disease process compromises the myocardium's ability to contract, which thereby alters the conduction pathways through the heart. A healthy heart has specialized conduction pathways in both the atria and the ventricles that enable the rapid conduction of excitation (i.e. depolarization) throughout the myocardium. Normally, the sinoatrial node (“SA node”) initiates each heart-beat cycle by depolarizing so as to generate an action potential. This action potential propagates relatively quickly through the atria, which react by contracting, and then relatively slowly through the atrio-ventricular node (“AV node”). From the AV node, activation propagates rapidly through the His-Purkinje system to the ventricles, which also react by contracting. This natural propagation synchronizes the contractions of the muscle fibers of each chamber and synchronizes the contraction of each atrium or ventricle with the contralateral atrium or ventricle.
- When a patient exhibits damage to the electrical system of the heart, as is often seen in patients with CHF, severe issues may arise. Disruption of the conductance pathways through the heart can cause a delay in the beginning of right or left ventricular systole and thereby induce asynchronous atrial and ventricular activation. Electrocardiographically, this dysynchrony is manifested as a long QRS interval. Alterations in ventricular contractility frequently compromise the ability of the failing heart to eject blood and may consequently increase the severity of the regurgitant flow through the mitral valve. In patients exhibiting these severe symptoms, the intraventricular conduction delays lead to clinical instability associated with a greatly increased risk of death.
- Since 2001, approximately 271,000 heart failure patients in the United States have received cardiac resynchronization therapy (“CRT”) to treat moderate to severe heart failure (“HF”). Conventional CRT methods employ a pacemaker to pace both ventricles of the heart such that the heart can resynchronize. CRT devices have three leads; the first positioned in the atrium, the second positioned in the right ventricle, and the third inserted through the coronary sinus to pace the left ventricle.
- Due to the required placement of the third lead, the implantation and maintenance of a CRT device are associated with a greater risk than the implantation and maintenance of a standard pacemaker device. Primarily, it is a difficult procedure to advance the pacing lead into the coronary sinus and cardiac veins and, thus, implantation fails in approximately 8% of patients. Further, in approximately 6% of patients, implantation is compromised by dissection or perforation of the coronary sinus or cardiac vein. Severe complications are associated with the inaccurate implantation of a pacing lead, including complete heart block, hemopericardium, and cardiac arrest (which, together, occurred in about 1.2% of patients).
- As accurate placement of the leads is critical, the ability to visualize a map or profile of the coronary sinus is important to ensure proper navigation. Conventionally, clinicians use cardiac angiography to visualize the lumen of the blood vessels and the heart chambers. Cardiac angiography typically involves using a combination of injections of radiocontrast agent or dye and x-ray fluoroscopy to visualize the position and size of blood within the heart. This process, however, is not particularly accurate and does not provide a detailed profile of the coronary sinus.
- Thus, there is a need for an efficient, accurate, easy to use, and reasonably priced technique for determining the longitudinal profile of the aorta and the coronary sinus.
- Various embodiments of devices, systems, and methods for localization of body lumen junctures are disclosed herein. At least some of the disclosed embodiments allow a clinician to identify desired anatomical structures with a higher spatial resolution than with conventional techniques. For example, in certain embodiments, a clinician may use embodiments of the devices, systems and methods disclosed herein to accurately identify various bifurcations branching off of the coronary sinus. A clinician may further use the embodiments described herein to accurately place a lead within a coronary sinus or a bifurcation branching therefrom. In certain other embodiments, a clinician may use embodiments of the devices, systems and methods disclosed herein to create a conductance profile of an aorta that is capable of showing the locations of lesions or other structures. In this manner, conductance profile can be used to accurately treat an aortic aneurysm by employing a stent.
- Some embodiments disclosed herein include systems for localizing a body lumen junction or other intraluminal structure. These systems comprise a catheter having a proximal end and a distal end for placement into a body lumen. The catheter may comprise a first electrode and a second electrode, and each of the first and second electrodes have a proximal end and a distal end; the distal ends of the first and second electrodes are located between the proximal and distal ends of the catheter. In some embodiments, the catheter may comprise a thin wire. The system further comprises a processor connected to the first and second electrodes of the catheter. The processor is capable of collecting conductance data to determine a profile of the body lumen. The conductance data is collected at a plurality of locations within the body lumen and determined at each of the plurality of locations when the distal ends of the first and second electrodes are immersed in a fluid within the body lumen. In some embodiments, the processor is also capable of calculating a cross-sectional area of the body lumen at each of the plurality of locations within the body lumen using the conductance data.
- For certain embodiments of such systems, the relevant body lumen comprises at least a portion of an atrium, coronary sinus, aorta, a pulmonary vein-atrial junction, a blood vessel, a biliary tract, or an esophagus. Indeed, many embodiments may be used in connection with any other body lumen that is suitable for access and localization.
- The body lumen may have at least some fluid inside, and the fluid may comprise blood or another suitable fluid, such as a solution of NaCl having a known conductivity. Certain embodiments of the catheter have a passageway for passing fluid through the catheter to the location of the distal ends of the first and second electrodes, such that the fluid passing through the passageway comes in contact with the distal ends of the first and second electrodes. For some embodiments, the conductance data is determined at each of a plurality of locations within the lumen when the distal ends of the first and second electrodes are immersed in a first fluid having a first conductivity and then a second fluid having a second conductivity. The conductance data may comprise a first conductance value determined at each of the plurality of locations when the distal ends of the first and second electrodes are immersed in the first fluid and a second conductance value determined at each of the plurality of locations when the distal ends of the first and second electrodes are immersed in the second fluid. The profile of the body lumen is therefore determined from the first and second conductance values collected from each of the plurality of locations, the first conductivity of the first fluid, and the second conductivity of the second fluid. The profile may consist of actual or relative values for cross-sectional areas or conductances.
- Many embodiments disclosed herein have a catheter with at least four electrodes, including at least two excitation electrodes and at least two detection electrodes. Further, in certain embodiments, the catheter may comprise a thin wire having at least four electrodes. Each of the electrodes has a proximal end and a distal end, wherein the proximal ends of the electrodes may be connected to the processor directly or indirectly. In at least some embodiments, the distal ends of the excitation electrodes are located between the proximal and distal ends of the catheter, and the distal ends of the detection electrodes are located between the distal ends of the excitation electrodes.
- Certain embodiments disclosed herein include a number of steps for localizing a junction or other structure within a body lumen, including providing an embodiment of a system as disclosed herein; introducing the catheter into the body lumen; providing electrical current flow to the body lumen through the catheter; measuring a first conductance value at a first location in the body lumen; moving the catheter to a second location in the body lumen; measuring a second conductance value at a second location in the body lumen; and determining a profile of the body lumen based on the first conductance value of the first location and the second conductance value of the second location. The profile of the body lumen resulting from such embodiments may include relative conductances and/or relative cross-sectional areas.
- For other embodiments, the actual values for the lumen conductance or cross-sectional area are determined by further injecting a known volume of a first solution having a first conductivity into the body lumen; injecting a second solution having a second conductivity into the body lumen, wherein the second solution has a second volume and wherein the second conductivity does not equal the first conductivity; measuring a second conductance value at the first location in the body lumen; calculating the conductance at the first location in the body lumen; measuring a first conductance value at a second location in the body lumen; and calculating the conductance at the second location in the body lumen. The determination of the profile of the body lumen may be based on the conductance of the first location, the conductance of the second location, and the conductivities of the first and second solutions. In addition, in some embodiments, the tissue is ablated after localization using the same catheter for both aspects of the procedure.
-
FIG. 1 shows the visual output of an embodiment of a catheter system for localization during an experiment of movement through an interior of a surgical glove; -
FIG. 2A shows the visual output of an embodiment of a catheter system for localization during an experiment of movement through an interior of a heart; -
FIG. 2B shows a mean lumen profile of an aorta as generated by one embodiment of a catheter system for localization; -
FIG. 2C shows a mean lumen profile of an aorta generated by one embodiment of a catheter system for localization and further comprising corrections for bifurcations; -
FIG. 3A shows an embodiment of a catheter for localization of a body lumen juncture; -
FIG. 3B shows another embodiment of a catheter for localization of a body lumen juncture; -
FIG. 3C shows an embodiment of a catheter for localization and ablation of a body lumen juncture; -
FIG. 4A shows another embodiment of a catheter for localization; -
FIG. 4B shows an embodiment of a balloon catheter having impedance measuring electrodes supported in front of the stenting balloon; -
FIG. 4C shows another embodiment of a balloon catheter having impedance measuring electrodes within and in front of the balloon; -
FIG. 4D shows an embodiment of a catheter having an ultrasound transducer within and in front of the balloon; -
FIG. 4E shows an embodiment of a guide catheter with wire and impedance electrodes; -
FIG. 4F shows an embodiment of a catheter with multiple detection electrodes; -
FIG. 5A shows an embodiment of a catheter in cross-section proximal to the location of the sensors showing the leads embedded in the material of the probe; -
FIG. 5B shows another embodiment of a catheter in cross-section proximal to the location of the sensors showing the leads run in separate lumens; -
FIG. 6 is a schematic of an embodiment of a system showing a catheter carrying impedance measuring electrodes connected to a data processor equipment and excitation unit for the measurement of conductance and/or cross-sectional area; -
FIG. 7A shows the detected filtered voltage drop as measured in the blood stream before and after injection of 1.5% NaCl solution; -
FIG. 7B shows the peak-to-peak envelope of the detected voltage shown inFIG. 7A ; -
FIG. 8A shows the detected filtered voltage drop as measured in the blood stream before and after injection of 0.5% NaCl solution; -
FIG. 8B shows the peak-to-peak envelope of the detected voltage shown inFIG. 8A ; -
FIG. 9 shows one embodiment of a catheter for localization being used in the treatment of an aortic aneurysm; -
FIG. 10 shows one embodiment of a treatment for an aortic aneurysm; -
FIG. 11A shows the voltage recorded by a conductance catheter with a radius of 0.55 mm for various size vessels (vessel radii of 3.1, 2.7, 2.3, 1.9, 1.5 and 0.55 mm for the six curves, respectively) when a 0.5% NaCl bolus is injected into the treatment site; and -
FIG. 11B shows the voltage recorded by a conductance catheter with a radius of 0.55 mm for various size vessels (vessel radii of 3.1, 2.7, 2.3, 1.9, 1.5 and 0.55 mm for the six curves, respectively) when a 1.5% NaCl bolus is injected into the treatment site. - It will be appreciated by those of skill in the art that the following detailed description of the disclosed embodiments is merely exemplary in nature and is not intended to limit the scope of the appended claims.
- During various medical procedures involving intraluminal insertion of catheters or other devices, proper navigation of the device through body lumens, such as blood vessels or the heart, is critical to the success of the procedure. This is especially true with respect to catheterization of the aorta and coronary sinus. Indeed, unless the tissue targeted for treatment or diagnosis is properly located, the procedure can be ineffective or, even worse, damaging. For example, with respect to treatment of an aortic aneurysm, a stent must be delivered to a disease-free landing zone adjacent to the aneurysm. In the event the stent is inaccurately placed—due to disorientation within the lumen or otherwise—a sufficient seal will not be achieved and the treatment will be ineffective.
- Similarly, in the treatment of ventricular fibrillation using CRT therapy, an electrical lead must be placed precisely within the coronary sinus through the ostium of the coronary sinus (the junction of the coronary sinus and the right atrium). Achieving the proper placement is an exceptionally difficult procedure, in part because there are various anatomical structures located within the right atrium that can be easily confused with the coronary sinus (e.g., the fossa ovalis, the custaclan ridge, etc.). These particular features of the heart do not show up well on a fluoroscope, therefore making the procedure quite difficult and time consuming for the clinician. Nevertheless, the clinician must be able to accurately insert the catheter into the coronary sinus without perforating the vessel or causing any trauma to the adjacent structures, all while the heart is beating. Having a clear map of the coronary sinus in the form of a lumen profile minimizes the risks involved with this procedure and drastically reduces the risk of damaging the surrounding structures. Accordingly, a number of the embodiments disclosed herein permit a clinician to readily locate a catheter, or other medical device, within a body lumen in relation to body lumen junctions or other anatomical structures within the lumen.
- In addition to being able to properly navigate body lumens, it is also beneficial to obtain accurate measurements of the luminal cross-sectional area in a targeted location as this enables accurate and scientific stent sizing and placement. Obtaining such accurate measurements can improve clinical outcomes by avoiding under or over deployment and under or over sizing of a stent which can cause acute closure or in-stent restenosis. At least one embodiment disclosed herein allows a clinician to accurately measure the luminal cross-sectional area of an organ or body lumen. This leads to proper localization of a targeted tissue, accurate stent sizing and placement, and increased favorable outcomes for certain medical procedures.
- In at least one embodiment, electrical conductance is measured within the body lumen and a profile of relative conductance values is displayed, while other embodiments use conductance data to calculate luminal cross-sectional areas and display a profile of relative cross-sectional areas along a portion of the lumen. These profiles enable the clinician to readily locate the targeted tissue for further treatment, such as for placement of a lead or stent.
- Many of the disclosed embodiments do not calculate an absolute value for a lumen's cross-sectional area, but instead measure electrical conductance through a portion of the lumen to form a profile of the lumen. Often, the profile comprises relative conductances taken along the lumen. However, because conductance is proportional to cross-sectional area, as explained herein, the profile can comprise relative cross-sectional areas that have been determined from the conductances taken along the lumen.
- By monitoring this profile during catheterization, the clinician can visualize the anatomical structure of the lumen. For example, using a push through or a pull back of a disclosed embodiment of a catheter through a lumen, a clinician is able to localize a junction or other architectural marker in the body lumen. Such a push through or pull back technique will reflect, in relative terms, the lumen's changes in conductance, and therefore its changes in cross-sectional area, as the catheter moves, thereby depicting changes in lumen structure across a distance. Based on such changes in lumen structure, a clinician can determine the locations of various anatomical markers of the lumen, as well as the location of the catheter in relation to those markers.
- In one example, localization of the junction between an aortic aneurysm and the healthy aortic wall is achieved by assessing the change in conductance (and therefore in cross-sectional area) of the lumen as the catheter is pulled through the aorta and passes the affected tissue. Once a specific lumen junction or other anatomical structure is localized, the clinician can better treat a targeted tissue at or near that identifying structure. Such treatment may include, for example and without limitation, angioplasty or stent delivery. Further, because clinicians can accurately visualize the anatomic structure of the lumen, a catheter may be inserted into even the smallest blood vessel with a high degree of accuracy (e.g., the coronary sinus).
- Experiments have demonstrated the ability of the disclosed embodiments to provide accurate and reliable feedback as to the location of a catheter within a body lumen. For instance, a surgical glove was filled with saline to simulate a left atrium (the palm) and pulmonary veins (the fingers). A catheter configured for localization as described herein was pulled back from inside a finger to the palm, thereby simulating the transition from a pulmonary vein to the atrium.
FIG. 1 shows theconductance profile 10 as the catheter was pulled back from a finger into the palm of the glove, then was pushed into a finger. As can be seen, the profile shows that the conductance of the palm was significantly larger than the conductance of the finger, and the transition or demarcation from the finger to the palm is apparent. Because conductance and cross-sectional area (“CSA”) are proportional (as discussed below),conductance profile 10 is proportional to the CSA profile (not shown) and distinguishes between the smaller cross-sectional area of the fingers and the larger cross-sectional area of the palm. - A similar pullback experiment was carried out in a heart. Starting from the pulmonary vein, a catheter configured for localization as described herein was pulled back from the pulmonary vein into the left atrium and ventricle.
FIG. 2 shows a conductance tracing 12 that reflects the conductance for each region of the body lumen as the catheter is pulled back over a distance of about 5 cm from a starting point in the pulmonary vein. The pulmonary vein can be clearly identified by reference to its relative conductance compared to those of the left atrium, the mitral valve, and the left ventricle. Indeed, the atrial CSA is significantly larger than that of the pulmonary vein, and the atrial CSA increases with distance away from the pulmonary vein-atrial junction. A reduction in CSA is then observed as the catheter approaches and crosses the mitral valve. Once the catheter progresses through the mitral valve into the ventricle, the CSA increases gradually. - Using conductance data like that shown in
FIG. 2 , a clinician can precisely obtain his or her orientation within the aorta, and thereby localize an aortic aneurysm. For example, the various points of bifurcation of the aorta can be identified using the type of conductance data shown inFIG. 2A . Specifically, inFIG. 2A , where the conductance data begins to increase, the data indicates that the luminal CSA has increased, especially when such an increase is drastic. - A conductance or impedance catheter measures conductance within a body lumen using a number of electrodes. Referring now to
FIG. 3A , there is shown aconductance catheter 400 configured to localize a body lumen junction using conductance measurements.Catheter 400 has aproximal end 405 and adistal end 410, which is suitable for introduction into a body lumen. In one embodiment,catheter 400 comprises a thin conductance wire that is capable of accessing the coronary sinus. In addition,catheter 400 includes a pair ofexcitation electrodes 415 and a pair ofdetection electrodes 420. Each ofexcitation electrodes 415 anddetection electrodes 420 has a proximal end that is capable of attachment to a processing system (not shown) and a distal end that is located oncatheter 400 betweenproximal end 405 anddistal end 410. The distal ends ofdetection electrodes 420 are located oncatheter 400 between the distal ends ofexcitation electrodes 415.Excitation electrodes 415 are configured to emit a measured electrical charge into the body lumen, whiledetection electrodes 420 detect the amount of the charge that travels through a fluid within the body lumen. As explained in more detail below, a processing system calculates the change in electrical charge to determine the conductance through the lumen at any given location in the lumen. - As shown in
FIG. 3A ,electrodes distal end 410 ofcatheter 400. However, the positioning of the electrodes is not limited to this distal end portion, but may be anywhere on the catheter that can assist in providing conductance information to the clinician. Furthermore, multiple sets of electrodes (seeFIG. 4F ) may also be used to provide additional information used for mapping the interior anatomical structure of an internal organ, vessel, or other body lumen. - A number of embodiments disclosed herein, such as the embodiment shown in
FIG. 3A , have at least two detection electrodes and two excitation electrodes. However, in the embodiment shown inFIG. 3B , only two electrodes are used.Catheter 425 has aproximal end 430 and adistal end 435, as well as afirst electrode 440 and asecond electrode 445. Each ofelectrodes catheter 425 betweenproximal end 430 anddistal end 435. Becausecatheter 425 has only two electrodes, each electrode must serve both the excitation function and the detection function. To enable a single electrode to send and measure the electrical charge, a delay must be added to the circuit. Additionally, a bipolar catheter must be stationary at the time of measurement, requiring the clinician to obtain a profile by moving the catheter to a desired location, stopping and taking a measurement, and then moving the catheter again. By contrast, tetrapolar catheters may take a continuous conductance measurement as the catheter is pulled or pushed through the body lumen, thereby giving a more detailed profile as compared to bipolar catheters. - Although at least some embodiments can properly measure lumen conductance in the presence of a bodily fluid (such as blood) within the lumen, certain other embodiments may use fluids injected into the body lumen to properly calculate lumen conductance and/or cross-sectional area, as explained herein. Therefore, some embodiments include a channel through which fluid is injected into the body lumen. In the embodiment shown in
FIG. 3C ,infusion passageway 490 is configured to permit such injection so that fluid flowing frompassageway 490 will flow at least to the location of the distal ends ofexcitation electrodes 470 anddetection electrodes 480. Thus, the fluid passing throughpassageway 490 into the lumen will come in contact with the distal ends ofexcitation electrodes 470 anddetection electrodes 480. - Referring now to
FIGS. 4A to 4F , several embodiments of catheters are illustrated. With reference to the embodiment shown inFIG. 4A , there is shown animpedance catheter 22 with fourelectrodes distal end 19 of the catheter.Electrodes electrodes - In addition,
catheter 22 possesses anoptional infusion passageway 35 located proximal toexcitation electrode 25, as well asoptional ports 36 for suction of contents of the body lumen or for infusion of fluid. The fluid to inject throughpassageway 35 orports 36 can be any biologically compatible fluid, but, for some circumstances disclosed herein, the conductivity of the fluid is selected to be different from that of blood. - In various embodiments, including for example the embodiment shown in
FIG. 4A , the catheter contains achannel 31 for insertion of a guide wire to stiffen the flexible catheter during insertion or data recording. Additionally,channel 31 may be used to inject fluid solutions of various concentrations (and various conductivities) into the body lumen of interest. Anadditional channel 32 may be connected to the catheter such that the electrical wires connected to the one or more electrodes on the catheter are directed throughchannel 32 and to a data processor, such as data processor system 100 (seeFIG. 6 ), through anadaptor interface 33, such as an impedance module plug or the like, as described in more detail below. - In addition to localization, some embodiments disclosed herein provide other functionality.
FIGS. 4B-4F show a number of embodiments of conductance catheters having various functions. For example, several such embodiments include an angioplasty balloon, in addition to impedance electrodes (see, e.g.,FIG. 4B ). Such catheters may include electrodes for accurate detection of organ luminal cross-sectional area and ports for pressure gradient measurements. Hence, when using such catheters, it is not necessary to change catheters during the procedure, as with the current use of intravascular ultrasound. In at least one embodiment, the catheter can provide direct measurement of the non-stenosed area of the lumen, thereby allowing the selection of an appropriately sized stent for implantation. - With reference to the embodiment shown in
FIG. 4B , four wires are threaded through one of the two lumens of catheter 20 (a 4 Fr. catheter).Catheter 20 has a proximal end and adistal end 19, as well asexcitation electrodes detection electrodes distal end 19. Proximal to these electrodes is an angioplasty or stentingballoon 30 capable of being used to treat stenosis. The distance between the balloon and the electrodes is usually small, in the 0.5 mm to 2 cm range, but can be closer or farther away, depending on the particular application or treatment involved. The portion ofcatheter 20 withinballoon 30 includes aninfusion passageway 35 and apressure port 36. -
Detection electrodes excitation electrodes - In one approach, dimensions of a catheter to be used for any given application depend on the optimization of the potential field using finite element analysis described below. For small organs or in pediatric patients, the diameter of the catheter may be as small as 0.3 mm. In large organs, the diameter may be significantly larger depending on the results of the optimization based on finite element analysis. The balloon will typically be sized according to the preferred dimension of the organ after the distension. The balloon may be made of materials suitable for the function, such as, for example, polyethylene, latex, polyestherurethane, or combinations thereof. In at least one embodiment, the balloon comprises a thickness of a few microns. The catheter may comprise PVC or polyethylene material, although other materials may be used equally well. The tip of the catheter can be straight, curved, or angled to facilitate insertion into the coronary arteries or other body lumens, such as, for example, the biliary tract.
- Referring again to
FIG. 4B ,catheter 20 may also include several miniature pressure transducers (not shown) carried by the catheter or pressure ports for determining the pressure gradient proximal to the site where the conductance is measured. The pressure is preferably measured inside the balloon and proximal to, distal to, and at the location of the conductance measurement, and locations proximal and distal thereto, thereby enabling the measurement of pressure recordings at the site of stenosis and also the measurement of pressure-difference along or near the stenosis. In one embodiment, shown inFIG. 4B ,catheter 20 includespressure port 90 andpressure port 91 proximal to or at the site of the conductance measurement for evaluation of pressure gradients. As described below with reference toFIGS. 5A , 5B, and 6, in at least one embodiment, the pressure ports are connected by respective conduits incatheter 20 to pressure sensors in the data processor system 100 (seeFIG. 6 ). Such pressure sensors are well known in the art and include, for example, fiber-optic systems, miniature strain gauges, and perfused low-compliance manometry. - In at least one embodiment, a fluid-filled silastic pressure-monitoring catheter is connected to a pressure transducer. Luminal pressure can be monitored by a low compliance external pressure transducer coupled to the infusion channel of the catheter. Pressure transducer calibration was carried out by applying 0 and 100 mmHg of pressure by means of a hydrostatic column.
- In another embodiment, shown in
FIG. 4C , acatheter 39 includes another set ofexcitation electrodes detection electrodes balloon 30 for accurate determination of the balloon cross-sectional area during angioplasty or stent deployment. These electrodes are in addition toelectrodes - In various embodiments, the conductance may be measured using a two-electrode system (see
FIG. 4D ). In other embodiments, such as illustrated inFIG. 4F , the conductances at several locations can be measured at the same time using an array of five or more electrodes. Here,excitation electrodes detection electrodes - In another embodiment, shown in
FIG. 4D ,catheter 21 has one or more imaging or recording devices, such as, for example,ultrasound transducers 50 for cross-sectional area and wall thickness measurements. As shown,transducers 50 are located neardistal end 19 ofcatheter 21. - With reference to the embodiment shown in
FIG. 4E ,electrodes wire 18, such as, for example, a pressure wire, and inserted through aguide catheter 23, where the infusion of a bolus can be made through the lumen of the guide catheter.Adaptor interface 33 may be used to house and guide the electrical wires (including proximal portions of the excitation and detection electrodes) to adata processor system 100, while aside channel 34 is used to inject various fluids intocatheter 23. In yet another embodiment (not illustrated), the catheter includes a sensor for measurement of the flow of fluid in the body lumen. - Many of the embodiments described herein may be used as part of a system, which includes suitable connections between the system's various parts. As described below with reference to
FIGS. 5A , 5B, and 6, the excitation and detection electrodes are electrically connected to electrically conductive leads in the catheter for connecting the electrodes to thedata processor system 100. -
FIGS. 5A and 5B illustrate cross-sectional views of twoembodiments 20A and 20B of a catheter such ascatheter 20 shown inFIG. 4B . Each embodiment has alumen 60 for inflating and deflating the balloon and alumen 61 for suction and infusion. The sizes of these lumens can vary. The electrode leads 70A are embedded in the material of the catheter in the embodiment shown inFIG. 5A , whereas the electrode leads 70B are tunneled through alumen 71 formed within the body of catheter 20B shown inFIG. 5B . - Pressure conduits for perfusion manometry connect
pressure ports data processor system 100. As shown inFIG. 5A ,pressure conduits 95A may be formed incatheter 20A. In another embodiment, shown inFIG. 5B ,pressure conduits 95B constitute individual conduits within atunnel 96 formed in catheter 20B. In the embodiments described above where miniature pressure transducers are carried by the catheter, electrical conductors may be substituted for these pressure conduits. - With reference to
FIG. 6 , in at least some embodiments,catheter 20 connects to adata processor system 100, to a manual orautomatic system 105 for distension of the balloon, and to asystem 106 for infusion of fluid or suction of blood or other bodily fluid. The fluid for infusion may be heated withheating unit 107 to between 37° C. and 39° C. or to body temperature. The impedance planimetry system typically includes a constant current unit, amplifiers, and signal conditioners, but variations are possible. The pressure system typically includes amplifiers and signal conditioners. The system can optionally contain signal conditioning equipment for recording of fluid flow in the body lumen. - In at least one embodiment, the system is pre-calibrated and a catheter is available in a package. The package also may contain sterile syringes with fluids to be injected. The syringes are attached to the machine, and after heating of the fluid by the machine and placement of the catheter in the body lumen of interest, the user presses a button that initiates the injection with subsequent computation of the desired parameters. The CSA, parallel conductance, and/or other relevant measures, such as distensibility, tension, etc., will typically appear on the display panel in the
PC module 160. The user can then treat the aortic aneurysm by placement of a stent. - If more than one CSA is measured at the same time, the system can contain a multiplexer unit or a switch between CSA channels. In at least one embodiment, each CSA measurement or pressure measurement will be through separate amplifier units.
- In at least one embodiment, the impedance and pressure data are analog signals which are converted by analog-to-digital converters 150 and transmitted to a
computer 160 for on-line display, on-line analysis, and storage. In other embodiments, all data handling is done on an entirely analog basis. - The processor system includes software programs for analyzing the conductance data. Additional software calculates cross-sectional areas based on a number of categories of data, as disclosed herein. However, as discussed in more detail below, to calculate for absolute cross-sectional values, certain errors must be reduced or eliminated. The software can be used to reduce the error in CSA values due to conductance of current in the lumen wall and surrounding tissue and to display the two-dimensional or three-dimensional geometry of the CSA distribution along the length of the vessel (and, optionally, along with the pressure gradient). In one embodiment of the software, a finite element approach or a finite difference approach is used to derive the CSA of organ stenosis, taking parameters such as conductivities of the fluid in the lumen and of the lumen wall and surrounding tissue into consideration.
- In another embodiment, simpler circuits are used. As explained herein, absolute cross-sectional values may be calculated based on two or more injections of different NaCl solutions, which varies the conductivity of fluid in the lumen. In other embodiments, the software contains the code for reducing the error in luminal CSA measurement by analyzing signals during interventions, such as infusion of a fluid into the lumen or by changing the amplitude or frequency of the current from the current amplifier. The software chosen for a particular application may allow for computation of the CSA with only a small error instantly or within acceptable time during the medical procedure.
- Referring now to
FIG. 4A ,catheter 22 measures conductance in the body lumen by detecting the change in voltage betweendetection electrodes -
- Thus, the change in voltage, ΔV, is equal to the magnitude of the current, I, multiplied by the distance between the detection electrodes, L, divided by the conductivity of the fluid in the lumen, C, and divided by the cross-sectional area, CSA. Because the current (I), the distance (L), and the conductivity (C) normally can be regarded as calibration constants during a localization procedure, an inversely proportional relationship exists between the voltage difference and the CSA, as shown by the following equation:
-
- In other words, as the cross-sectional area of the lumen decreases, the change in voltage measured by
catheter 22 increases. As discussed earlier, conductance and cross-sectional area are proportional. Thus, this equation permits the relative conductances or cross-sectional areas of various intralumen anatomical structures to be determined from measurement of the change in voltage across the lumen using at least one excitation electrode and one detection electrode. - This measurement, however, does not produce accurate, or absolute, values of conductance or CSA because the wall of the lumen and surrounding tissue effectuate a loss of current. Further, when the impedance electrode encounters a bifurcation, the measured conductance over estimates the segment area. This error is related to the dimension of the bifurcation and the angle of the branch, with an angle of 90° resulting in the largest error. As shown in
FIG. 2B , the amplitude of the conductance is related to the size of the aortic branches; for example, the conductance spike (increase in conductance) resulting from the thoracic branches is smaller than the conductance spike formed when the catheter is pulled past the abdominal branches. Although relying on the relative conductances or CSAs is sufficient for the localization of intraluminal structures, other embodiments for other purposes may require the accurate determination of absolute values for CSAs. - At least some of the disclosed embodiments overcome the problems associated with determination of the size (cross-sectional area) of luminal organs, such as, for example, in the coronary arteries, carotid, femoral, renal and iliac arteries, aorta, gastrointestinal tract, urethra, and ureter. In addition, at least some embodiments also provide methods for registration of acute changes in wall conductance, such as, for example, due to edema or acute damage to the tissue, and for detection of muscle spasms/contractions.
- The operation of
catheter 20, shown inFIG. 4B , is as follows: forelectrodes -
- where Gp(z,t) is the effective conductance of the structure outside the bodily fluid (organ wall and surrounding tissue); Cb is the specific electrical conductivity of the bodily fluid, which for blood generally depends on the temperature, hematocrit, and orientation and deformation of blood cells; and L is the distance between the detection electrodes. This equation shows that conductance, G(z,t), is proportional to the cross-sectional area, CSA (z,t). Thus, a larger conductance will reflect a larger cross-sectional area, and vice versa.
- Equation [2a] can be rearranged to solve for cross-sectional area CSA(z,t), with a correction factor, a, if the electric field is non-homogeneous, as
-
- where α would be equal to 1 if the field were completely homogeneous. The parallel conductance, Gp, is an offset error that results from current leakage. Gp would equal 0 if all of the current were confined to the blood and hence would correspond to the cylindrical model given by Equation [1a]. In one approach, finite element analysis is used to properly design the spacing between detection and excitation electrodes relative to the dimensions of the body lumen to provide a nearly homogenous field such that cc can be considered equal to 1. Simulations show that a homogenous or substantially homogenous field is provided by (1) the placement of detection electrodes substantially equidistant from the excitation electrodes and (2) maintaining the distance between the detection and excitation electrodes substantially comparable to the body lumen diameter. In one approach, a homogeneous field is achieved by taking steps (1) and/or (2) described above so that a equals 1 in the foregoing analysis.
- Gp is a constant at any given position, z, along the long axis of a body lumen, and at any given time, t, in the cardiac cycle. Hence, two injections of different concentrations (and therefore conductivities) of NaCl solution give rise to two equations:
-
C 1·CSA(z,t)+L·G p(z,t)=L·G 1(z,t) [3] -
C 2·CSA(z,t)+L·G p(z,t)=L·G 2(z,t) [4] - which can be solved simultaneously for CSA and Gp as
-
- where subscript “1” and subscript “2” designate any two injections of different NaCl concentrations (and conductivities). For each injection k, Ck gives rise to Gk which is measured as the ratio of the root mean square of the current divided by the root mean square of the voltage. The Ck is typically determined through in vitro calibration for the various NaCl concentrations. The concentration of NaCl used is typically on the order of 0.45% to 1.8%. The volume of NaCl solution is typically about 5 ml, but the amount of solution should be sufficient to momentarily displace the entire local vascular blood volume or other body lumen fluid. The values of CSA(t) and Gp(t) can be determined at end-diastole or end-systole (i.e., the minimum and maximum values) or the mean thereof. The value of CSA would vary through the cardiac cycle, but Gp(t) does not vary significantly.
- Once the CSA and Gp of the body lumen are determined according to the above embodiment, rearrangement of Equation [2a] allows the calculation of the specific electrical conductivity of bodily fluid in the presence of fluid flow as
-
- In this way, Equation [2b] can be used to calculate the CSA continuously (temporal variation, as for example through the cardiac cycle) in the presence of bodily fluid.
- In one approach, a pull or push through is used to reconstruct the body lumen CSA along its length. During a long injection of solution (e.g., 10 s to 15 s), the catheter can be pulled back or pushed forward at constant velocity U. Equation [2a] can be expressed as
-
- where the axial position, z, is the product of catheter velocity, U, and time, t; i.e., z=U·t.
- For the two injections, denoted by subscript “1” and subscript “2”, respectively, different time points T1, T2, etc. may be considered such that Equation [8] can be written as
-
- and so on. Each set of Equations [9a], [9b] and [10a], [10b], etc., can be solved for CSA1p1 and CSA2, Gp2, respectively. Hence, one can measure the CSA at various time intervals and therefore at different positions along the body lumen to reconstruct the length of the lumen. In at least one embodiment, the data on the CSA and parallel conductance as a function of longitudinal position along the body lumen can be exported from an electronic spreadsheet, such as, for example, a Microsoft Excel file, to diagramming software, such as AutoCAD®, where the software uses the coordinates to render a three-dimensional depiction of the lumen on the monitor.
- For example, in one approach, the pull back reconstruction was made during a long injection where the catheter was pulled back at constant rate by hand. The catheter was marked along its length such that the pull back was made at 2 mm/sec. Hence, during a 10-second injection, the catheter was pulled back about 2 cm. The data was continuously measured and analyzed at every two second interval; i.e., at every 4 mm. Thus, six different measurements of CSA and Gp were taken which were used to reconstruct the CSA and Gp along the length of the 2 cm segment.
- In an additional embodiment, the wall thickness is determined from the parallel conductance for those body lumens that are surrounded by air or non-conducting tissue. In such cases, the parallel conductance is equal to
-
- where CSAW is the CSA of the lumen wall and CW is the electrical conductivity of the wall. This equation can be solved for CSAW as
-
- For a cylindrical body lumen, the wall thickness, h, can be expressed as
-
- where D is the diameter of the lumen, which can be determined from the circular
-
CSA(D=[4CSA/π]1/2) - When the CSA, pressure, wall thickness, and flow data are determined according to the embodiments outlined above, it is possible to compute the compliance (e.g., ΔCSA/ΔAP), tension (e.g., P*r, where P and r are the intraluminal pressure and radius of a cylindrical lumen), stress (e.g., P*r/h, where h is the wall thickness of the cylindrical organ), strain (e.g., (C−Cd)/Cd where C is the inner circumference and Cd is the circumference in diastole), and wall shear stress (e.g., 4 πQ/r3 where, μ, Q, and r are the fluid viscosity, flow rate, and radius of the cylindrical lumen for a fully developed flow). These quantities can be used in assessing the mechanical characteristics of the system in health and disease.
- In at least one approach for localization or measuring the conductance (and determining the cross-sectional area) of a body lumen, a catheter is introduced from an exteriorly accessible opening (for example, the mouth, nose, or anus for GI applications, or the mouth or nose for airway applications) into the targeted body lumen. For cardiovascular applications, the catheter can be inserted into the lumens in various ways, such as, for example, those used in conventional angioplasty. In at least one embodiment, an 18 gauge needle is inserted into the femoral artery followed by an introducer. A guide wire is then inserted into the introducer and advanced into the lumen of the femoral artery. A 4 or 5 Fr. conductance catheter is then inserted into the femoral artery via wire, and the wire is subsequently retracted. The catheter tip containing the conductance electrodes can then be advanced to the region of interest by use of x-ray (e.g., fluoroscopy). In another approach, this methodology is used on small to medium size vessels (e.g., femoral, coronary, carotid, iliac arteries).
- In at least one example of a clinical application, obtaining an accurate measurement (within acceptable limits) of the luminal cross-sectional area of an aortic aneurysm enables accurate and scientific stent sizing and placement. Proper stent implantation improves clinical outcomes by avoiding under or over deployment and under or over sizing of a stent, which can cause acute closure or in-stent re-stenosis. In at least one embodiment, an angioplasty or stent balloon includes impedance electrodes supported by the catheter in front of the balloon. As described herein, these electrodes enable the immediate, or real-time determination of the cross-sectional area of the vessel during the balloon advancement. This provides a direct measurement of non-stenosed area and allows for the appropriate stent size to be selected. In one approach, impedance electrodes are located in the center of the balloon in order to deploy the stent to the desired cross-sectional area. Such embodiments and procedures substantially improve the accuracy of stenting and the outcome of such stenting, as well as reduce overall costs.
- In another embodiment, error due to the loss of current in the wall of the organ and surrounding tissue is corrected by injection of two solutions of NaCl or other solutions with known conductivities. In one approach, a minimum of two injections with different concentrations of NaCl (and, therefore, different conductivities) are required to solve for the two unknowns, CSA and Gp. However, in other embodiments disclosed herein, only relative values for conductance or cross-sectional area are necessary, so the injection of two solutions is not necessary. In another approach, three injections will yield three sets of values for CSA and Gp (although not necessarily linearly independent), while four injections would yield six sets of values. In one approach, at least two solutions (e.g., 0.5% and 1.5% NaCi solutions) are injected in the targeted vessel or other lumen. Studies indicate that an infusion rate of approximately 1 ml/s for a five second interval is sufficient to displace the blood volume and results in a local pressure increase of less than 10 mmHg in the coronary artery. This pressure change depends on the injection rate which should be comparable to the lumen flow rate.
- In at least one approach, involving the application of Equations [5] and [6], the vessel is under identical or very similar conditions during the two injections. Hence, some variables, such as the infusion rate, bolus temperature, etc., are similar for the two injections. Typically, a short time interval is to be allowed (1 to 2 minute period) between the two injections to permit the vessel to return to homeostatic state. This can be determined from the baseline conductance as shown in
FIGS. 7A , 7B, 8A, or 8B. The parallel conductance is preferably the same or very similar during the two injections. Dextran, albumin, or another large molecular weight molecule may be added to the NaCl solutions to maintain the colloid osmotic pressure of the solution to reduce or prevent fluid or ion exchange through the vessel wall. - In yet another embodiment, the NaCl solution is heated to body temperature prior to injection since the conductivity of current is temperature dependent. Alternatively, the injected bolus is at room temperature, but a mathematical temperature correction is made since the conductivity is related to temperature in a linear fashion.
- In one approach, a sheath is inserted through either the femoral artery or the carotid artery in the direction of flow. To access the lower anterior descending (“LAD”) artery, the sheath is inserted through the ascending aorta. For the carotid artery, where the diameter is typically on the order of 5 mm to 5.5 mm, a catheter having a diameter of 1.9 mm can be used, as determined from finite element analysis, discussed further below. For the femoral and coronary arteries, where the diameter is typically in the range from 3.5 mm to 4 mm, so a catheter of about 0.8 mm diameter would be appropriate. The catheter can be inserted into the femoral, carotid, or LAD artery through a sheath appropriate for the particular treatment. Measurements for all three vessels can be made similarly.
- At least one clinical application of the embodiments of the systems and methods disclosed herein relates to the delivery of pacing leads used in CRT, and, in particular, the delivery of a coronary sinus lead. When CRT is employed, it is necessary to advance a lead into the coronary sinus and coronary veins branching therefrom in order to position the electrode(s) adjacent to the left ventricle of the heart. During delivery, the distal end of the coronary lead is advanced through the superior vena cava, the right atrium, the valve of the coronary sinus, the coronary sinus, and may be further advanced into a coronary vein communicating with the coronary sinus, such as the great cardiac vein. Routing a lead along the desired path to implant the electrode in the desired implantation site can be difficult. This is particularly true with respect to steering leads through the coronary sinus and into a branching vein on the left myocardium (posterior lateral branch). The relatively small diameter of the coronary veins of the heart, the various anomalies typical in vascular anatomy, and the number of branch veins associated with the anatomy make locating the desired path challenging. Using the catheters and systems disclosed herein, it is possible to obtain precise measurements of the coronary sinus and related branching blood vessels, to facilitate the navigation of such difficult areas. In other words, the catheters and systems disclosed herein can obtain an accurate profile of the coronary venous system, including accurate identification of bifurcations along the length of the coronary sinus.
- In at least one embodiment, a conductance catheter comprising a thin wire may be employed for delivering a lead into the coronary sinus or a bifurcation branching therefrom. In this embodiment, the conductance wire can be pulled through the coronary sinus and used to create a conductance profile thereof. In this manner, a clinician can accurately identify—with a high degree of specificity—the various bifurcations branching from the coronary sinus. The clinician can identify the bifurcation of interest and thereafter steer the conductance wire therein. Once the wire is positioned within the bifurcation, the lead can be inserted over the wire and placed within the desired bifurcation. This application can be conducted using the larger conductance catheters described herein as well; however, the relatively small diameter of a conductance catheter comprising a wire facilitates navigation through the narrow bifurcations branching from the coronary sinus.
- Described herein are the protocol and results for one approach that are generally applicable to most arterial vessels. The conductance catheter was inserted through the sheath for a particular vessel of interest. A baseline reading of voltage was continuously recorded. Two containers containing 0.5% and 1.5% NaCl were placed in temperature bath and maintained at 37° C. A 5 ml to 10 ml injection of 1.5% NaCl was made over a 5 second interval. The detection voltage was continuously recorded over a 10 second interval during the 5 second injection. Several minutes later, a similar volume of 1.5% NaCl solution was injected at a similar rate. The data was again recorded. Matlab® was used to analyze the data including filtering with high pass and with low cut off frequency (1200 Hz). The data was displayed using Matlab®, and the mean of the voltage signal during the passage of each respective solution was recorded. The corresponding currents were also measured to yield the conductance (G=I/V). The conductivity of each solution was calibrated with six different tubes of known CSA at body temperature. A model using Equation [1a] was fitted to the data to calculate conductivity C. The analysis was carried out with SPSS statistical software using the non-linear regression fit. Given C and G for each of the two injections, an Excel spreadsheet file was formatted to calculate the CSA and Gp as per equations [5] and [6], respectively. These measurements were repeated several times to determine the reproducibility of the technique. The reproducibility of the data was within 5%. Ultrasound was used to measure the diameter of the vessel simultaneous with our conductance measurements. The detection electrodes were visualized with ultrasound, and the diameter measurements was made at the center of the detection electrodes. The maximum differences between the conductance and ultrasound measurements were within 10%.
-
FIGS. 7A , 7B, 8A, and 8B illustrate voltage measurements in the blood stream in the left carotid artery. Here, the data acquisition had a sampling frequency of 75 KHz, with two channels—the current injected and the detected voltage, respectively. The current injected has a frequency of 5 KHz, so the voltage detected, modulated in amplitude by the impedance changing through the bolus injection, will have a spectrum in the vicinity of 5 KHz. - With reference to
FIG. 7A there is shown a signal processed with a high pass filter with low cut off frequency (1200 Hz). The top andbottom portions FIG. 7B . The initial 7 seconds correspond to the baseline; i.e., electrodes in the blood stream. The next 7 seconds correspond to an injection of hyper-osmotic NaCl solution (1.5% NACI). It can be seen that the voltage is decreased, implying increased conductance (since the injected current is constant). Once the NaCl solution is washed out, the baseline is recovered as shown inFIGS. 7A and 7B .FIGS. 8A and 8B show similar data corresponding to 0.5% NaCl solutions. - The voltage signals are ideal since the difference between the baseline and the injected solution is apparent and systematic. Furthermore, the pulsation of vessel diameter can be seen in the 0.5% and 1.5% NaCl injections (
FIGS. 7A , 7B and 8A, 8B, respectively). This allows determination of the variation of CSA throughout the cardiac cycle as outline above. - The NaCl solution can be injected by hand or by using a mechanical injector to momentarily displace the entire volume of blood or bodily fluid in the lumen segment of interest. For example, in a blood vessel, the pressure generated by the injection will not only displace the blood in the antegrade direction (in the direction of blood flow) but also in the retrograde direction (by momentarily pushing the blood backwards). In other visceral organs which may be normally collapsed, the NaCl solution will not displace blood as in the vessels but will merely open the organs and create a flow of the fluid. In one approach, after injection of a first solution into the treatment or measurement site, sensors monitor and confirm baseline of conductance prior to injection of a second solution into the treatment site.
- The injections described above are preferably repeated at least once to reduce errors associated with the administration of the injections, such as, for example, where the injection does not completely displace the blood or where there is significant mixing with blood. As previously noted, any bifurcation(s) (with branching angle near 90°) near the targeted lumen can cause an overestimation of the calculated CSA, thereby resulting in a conductance spike (see
FIG. 2B ). Hence, generally the catheter should be slightly retracted or advanced and the measurement repeated. An additional application with multiple detection electrodes or a pull back or push forward during injection will accomplish the same goal. Here, an array of detection electrodes can be used to minimize or eliminate errors that would result from bifurcations or branching in the measurement or treatment site. - In at least one embodiment, conductance spikes when present can be eliminated or smoothed out through a number or computational processing means, including, without limitation, threshold limits, gradient, interpolation, and smoothing algorithms. Threshold limits can be programmed to ignore readings for points where the cross-sectional area is greater than a preset number. Threshold limits are convenient to program; however, using solely threshold limits will not allow for differentiation between bifurcations caused by luminal branches and those caused by conditions such as aneurysms. Accordingly, consideration of the gradient (slope) where a conductance spike would correspond to a large, or possibly infinite, gradient. This criterion can be used in conjunction with a smoothing algorithm (e.g., linear interpolation or cubic spline) to distinguish a bifurcation from a pathological condition. Now referring to
FIG. 2C , the data ofFIG. 2B is shown after the conductance spikes have been eliminated using at least one computational processing means. Similar profiles can be generated for the coronary sinus and, as such, the effective and convenient navigation thereof can be achieved. The width of the conductance spike (not shown) can represent the approximate size (or diameter) of the bifurcation. - In an alternative approach, error due to the eccentric position of the electrode or other imaging device can be reduced by inflation of a balloon on the catheter. The inflation of the balloon during measurement will place the electrodes or other imaging device in the center of the vessel away from the wall. In the case of impedance electrodes, the inflation of the balloon can be synchronized with the injection of a bolus such that the balloon inflation would immediately precede the bolus injection. Our results, however, show that the error due to catheter eccentricity is small.
- The CSA predicted by Equation [5] corresponds to the area of the vessel or other lumen external to the catheter (i.e., CSA of vessel minus CSA of catheter). If the conductivity of the NaCl solutions is determined by calibration from Equation [1a] with various tubes of known CSA, then the calibration accounts for the dimension of the catheter and the calculated CSA corresponds to that of the total vessel lumen. In at least one embodiment, the calibration of the CSA measurement system will be performed at 37° C. by applying 100 mmHg in a solid polyphenolenoxide block with holes of known CSA ranging from 7.065 mm2 (3 mm in diameter) to 1017 mm2 (36 mm in diameter). However, if the conductivity of the solutions is obtained from a conductivity meter independent of the catheter, then the CSA of the catheter is generally added to the CSA computed from Equation [5] to give the total CSA of the vessel.
- The signals are generally non-stationary, nonlinear, and stochastic. To deal with non-stationary stochastic functions, one can use a number of methods, such as the Spectrogram, the Wavelet's analysis, the Wigner-Ville distribution, the Evolutionary Spectrum, Modal analysis, or the intrinsic model function (“IMF”) method. The mean or peak-to-peak values can be systematically determined by the aforementioned signal analysis and used in Equation [5] to compute the CSA.
- For the determination of conductance or cross-sectional area of a heart valve, it is generally not feasible to displace the entire volume of the heart. Hence, the conductivity of the blood is transiently changed by injection of a hypertonic NaCl solution into the pulmonary artery. If the measured total conductance is plotted versus blood conductivity on a graph, the extrapolated conductance at zero conductivity corresponds to the parallel conductance. In order to ensure that the two inner electrodes are positioned in the plane of the valve annulus (2 mm to 3 mm), in one embodiment, two
pressure sensors 36 are placed immediately proximal and distal to (1 mm to 2 mm above and below, respectively) the detection electrodes or sets of detection electrodes (see, e.g.,FIGS. 4A and 4F ). The pressure readings will then indicate the position of the detection electrode relative to the desired site of measurement (aortic valve: aortic-ventricular pressure; mitral valve: left ventricular-atrial pressure; tricuspid valve: right atrial-ventricular pressure; pulmonary valve: right ventricular-pulmonary pressure). The parallel conductance at the site of annulus is generally expected to be small since the annulus consists primarily of collagen, which has low electrical conductivity. In another application, a pull back or push forward through the heart chamber will show different conductance due to the change in geometry and parallel conductance. This can be established for normal patients, which can then be used to diagnose valvular stenosis. - In one approach, for the esophagus or the urethra, the procedures can conveniently be done by swallowing fluids of known conductivities into the esophagus and infusion of fluids of known conductances into the urinary bladder followed by voiding the volume. In another approach, fluids can be swallowed or urine voided followed by measurement of the fluid conductivities from samples of the fluid. The latter method can be applied to the ureter where a catheter can be advanced up into the ureter and fluids can be injected from a proximal port on the probe (will also be applicable in the intestines) or urine production can be increased and samples taken distal in the ureter during passage of the bolus or from the urinary bladder.
- In one approach, concomitant with measuring the conductance, cross-sectional area, and/or pressure gradient at the treatment or measurement site, a mechanical stimulus is introduced by way of inflating the balloon or by releasing a stent from the catheter, thereby facilitating flow through the stenosed part of the lumen.
- In another approach, concomitant with measuring the conductance, cross-sectional area, and/or pressure gradient at the treatment site, one or more pharmaceutical substances for diagnosis or treatment of stenosis is injected into the treatment site. For example, in one approach, the injected substance can be a smooth muscle agonist or antagonist. In yet another approach, concomitant with measuring the conductance, cross-sectional area, and/or pressure gradient at the treatment site, an inflating fluid is released into the treatment site for release of any stenosis or materials causing stenosis in the lumen or treatment site.
- Again, it will be noted that the methods, systems, and catheters described herein can be applied to any body lumen or treatment site. For example, the methods, systems, and catheters described herein can be applied to any one of the following hollow bodily systems: the cardiovascular system including the heart; the digestive system; the respiratory system; the reproductive system; and the urogenital tract.
- Finite Element Analysis: In one preferred approach, finite element analysis (“FEA”) is used to verify the validity of Equations [5] and [6]. There are two major considerations for the model definition: geometry and electrical properties. The general equation governing the electric scalar potential distribution, V, is given by Poisson's equation as:
-
∇·(C∇V)=−1 [13] - where C, I and ∇ are the conductivity, the driving current density, and the del operator, respectively. Femlab or any standard finite element package can be used to compute the nodal voltages using Equation [13]. Once V has been determined, the electric field can be obtained from E=−∇V.
- The FEA allows for the determination of the nature of the field and its alteration in response to different electrode distances, distances between driving electrodes, wall thicknesses, and wall conductivities. The percentage of total current in the lumen of the vessel (% I) can be used as an index of both leakage and field homogeneity. Hence, the various geometric and electrical material properties can be varied to obtain the optimum design, i.e. minimizing the non-homogeneity of the field. Furthermore, the experimental procedure was simulated by injection of the two solutions of NaCl to verify the accuracy of Equation [5]. Finally, the effect of the presence of electrodes and the catheter in the lumen of vessel was assessed. The error terms representing the changes in measured conductance due to the attraction of the field to the electrodes and the repulsion of the field from the resistive catheter body were quantified.
- Poisson's equation was solved for the potential field, which takes into account the magnitude of the applied current, the location of the current driving and detection electrodes, and the conductivities and geometrical shapes in the model including the vessel wall and surrounding tissue. This analysis suggests that the following conditions are optimal for the cylindrical model: (1) the placement of detection (voltage sensing) electrodes equidistant from the excitation (current driving) electrodes; (2) the distance between the excitation electrodes should be much greater than the distance between the detection electrodes; and (3) the distance between the detection and excitation electrodes is comparable to the vessel diameter, or the diameter of the vessel is small relative to the distance between the driving electrodes. If these conditions are satisfied, the equipotential contours more closely resemble straight lines perpendicular to the axis of the catheter and the voltage drop measured at the wall will be nearly identical to that at the center. Since the curvature of the equipotential contours is inversely related to the homogeneity of the electric field, it is possible to optimize the design to minimize the curvature of the field lines. Consequently, in one approach, one or more of conditions (1)-(3) described above are met to increase the accuracy of the cylindrical model.
- Theoretically, it is impossible to ensure a completely homogeneous field given the current leakage through the lumen wall into the surrounding tissue. It was found that the iso-potential line is not constant as one moves out radially along the vessel as stipulated by the cylindrical model.
FIGS. 11A and 11B show the detected voltage for a catheter with a radius of 0.55 mm for two different NaCl solutions (0.5% and 1.5%, respectively). The origin corresponds to the center of the catheter. The firstvertical line 220 represents the inner part of the electrode which is wrapped around the catheter, and the secondvertical line 221 is the outer part of the electrode in contact with the solution (diameter of electrode is approximately 0.25 mm). The six different curves, top to bottom, correspond to six different vessels with radii of 3.1 mm, 2.7 mm, 2.3 mm, 1.9 mm, 1.5 mm, and 0.55 mm, respectively. It can be seen that a “hill” 220, 221 occurs at the detection electrodes, followed by a fairly uniform plateau in the vessel lumen, followed by an exponential decay into the surrounding tissue. Since the potential difference is measured at thedetection electrode - Thus, a number of the embodiments disclosed herein accurately calculate lumen cross-sectional area by measuring conductance and correcting for various errors inherent in such measurements. However, at least some of the disclosed embodiments provide for the localization of body lumen junctions and other intraluminal anatomical structures using relative conductances and/or cross-sectional areas. Because only relative differences in conductance or cross-sectional area are necessary for accurate localization, the calculation of absolute values for various locations within the body lumen may be skipped in most instances.
- Referring now to the embodiment shown in
FIG. 9 , one clinical application ofcatheter 22 is shown. Specifically,catheter 22 comprisingstent 160 is positioned within anaorta 140 for the treatment of anaortic aneurysm 145. As described above with respect toFIG. 4A , a set ofexcitation electrodes detection electrodes catheter 22, which is disposed withinstent 160. - In this embodiment,
catheter 22, and therebystent 160, is introduced into the blood stream percutaneously with a femoral approach. After the graft is routed into the aorta,electrodes catheter 22 as previously described herein. In one embodiment, prior to or concurrent with collecting the conductance data, thecatheter 22 may release fluid, such as a solution of NaCl having a known conductivity, into the aortic lumen, such that the fluid passing through the lumen comes into contact with the distal end of theelectrodes - Conductance data is collected at a plurality of locations throughout the
aorta 140 to determine a profile and cross-sectional area at various points along the aortic lumen. Further, any inherent errors in collected data can be corrected using any of the computational processes disclosed herein. In this manner, precise cross-sectional values of the aortic lumen can be obtained, as well as an accurate profile map of the region. Based on that data, the aneurysm can be precisely located within the aorta (e.g., where a larger conductance value is detected), and thestent 160 may be properly sized to affix to the aortic wall both distally and proximally of the aneurysm. - Now referring to
FIG. 10 , aballoon 30 is used to distendstent 160 within the aneurytic region of theaorta 140. Inflation of theballoon 30 applies a force to thestent 160 which extends radially and presses into the vessel wall just above and just below the aneurysm. As noted with respect to the embodiment shown inFIG. 9 , the profile and cross-sectional area of the aorta determined from the conductance data can be used to identify the optimal diameter to which theballoon 30 should be inflated. Accordingly, thestent 160 can be accurately sized to effectively treat the aneurysm. Furthermore, as the two necks of the graft should be deployed on an atherosclerosis-free aorta, the profile and cross-sectional area of the aorta determined from the conductance data can be used to identify a good landing zone for the deployment of the graft and thus prevent graft migration or endoleak. - While various embodiments of devices, systems, and methods for localization of body lumen junctures have been described in considerable detail herein, the embodiments are merely offered by way of non-limiting examples. Many variations and modifications of the embodiments described herein will be apparent to one of ordinary skill in the art in light of the disclosure. It will therefore be understood by those skilled in the art that various changes and modifications may be made, and equivalents may be substituted for elements thereof, without departing from the scope of the disclosure. Indeed, this disclosure is not intended to be exhaustive or to limiting. The scope of the disclosure is to be defined by the appended claims, and by their equivalents.
- Further, in describing representative embodiments, the disclosure may have presented a method and/or process as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described. As one of ordinary skill in the art would appreciate, other sequences of steps may be possible. Therefore, the particular order of the steps disclosed herein should not be construed as limitations on the claims. In addition, the claims directed to a method and/or process should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the sequences may be varied and still remain within the spirit and scope of the present disclosure.
- It is therefore intended that this description and the appended claims will encompass, all modifications and changes apparent to those of ordinary skill in the art based on this disclosure.
Claims (22)
1. A method for placing at least one lead within a heart, comprising the steps of:
providing a system, comprising:
a catheter having a proximal end and a distal end, the distal end of the catheter for placement into a blood vessel, the catheter comprising a first electrode and a second electrode, each of the first and second electrodes having a proximal end and a distal end, the distal ends of the first and second electrodes located between the proximal and distal ends of the catheter,
a lead for placement in a targeted area in a heart, the lead having a proximal end and a distal end, and wherein the distal end of the lead is removably coupled with the catheter; and
a processor connected to the first and second electrodes of the catheter, the processor capable of collecting conductance data to determine a profile of a blood vessel, the conductance data collected at a plurality of locations within the blood vessel and determined at each of the plurality of locations when the distal ends of the first and second electrodes are immersed in a fluid within the blood vessel;
determining the profile of the blood vessel through operation of the catheter and the processor;
using the profile of the blood vessel to identify the location of the targeted area; and
advancing the distal end of the catheter and the distal end of the lead through the blood vessel to the targeted area.
2. The method of claim 1 , further comprising the steps of:
positioning the distal end of the lead within the targeted area; and
withdrawing the catheter from the blood vessel.
3. The method of claim 2 , wherein the step of positioning the distal end of the lead within the targeted area further comprises steering the distal end of the lead into a bifurcation.
4. The method of claim 1 , wherein the step of determining the profile of the blood vessel through operation of the catheter and the processor further comprises the steps of:
providing constant electrical current flow to the blood vessel through the catheter;
measuring a first conductance value at a first location in the blood vessel;
moving the catheter to a second location in the blood vessel;
measuring a second conductance value at a second location in the blood vessel;
determining a profile of the blood vessel based on the first conductance value of the first location and the second conductance value of the second location.
5. The method of claim 1 , wherein the blood vessel comprises a coronary sinus.
6. The method of claim 5 , further comprising the steps of:
inserting the distal end of the catheter and the distal end of the lead into a femoral vein;
advancing the catheter and the lead through the vascular system to a right atrium of a heart;
determining a profile of the right atrium through operation of the catheter and the processor;
using the proof of the right atrium to identify the location of an ostium of the coronary sinus; and
advancing the distal end of the catheter and the distal end of the lead through the ostium and into the coronary sinus.
7. The method of claim 1 , wherein the processor further comprises a computational program capable of detecting the dimensions of the blood vessel or organ in real time.
8. The method of claim 1 , wherein the fluid comprises blood.
9. The method of claim 1 , wherein the profile of the blood vessel comprises relative conductances.
10. The method of claim 1 , wherein the profile of the blood vessel comprises relative cross-sectional areas.
11. The method of claim 1 , wherein:
the catheter further comprises a passageway for passing fluid through the catheter to the location of the distal ends of the first and second electrodes, such that fluid passing through the passageway comes in contact with the distal ends of the first and second electrodes;
the fluid within the blood vessel comprises a first fluid having a first conductivity and a second fluid having a second conductivity; and
the conductance data is determined at each of the plurality of locations when the distal ends of the first and second electrodes are immersed in each of the first fluid and the second fluid.
12. The method of claim 11 , further comprising:
injecting a known volume of a first solution having a first conductivity into the blood vessel;
injecting a second solution having a second conductivity into the blood vessel, wherein the second solution has a second volume and wherein the second conductivity does not equal the first conductivity;
measuring a second conductance value at the first location in the blood vessel;
calculating the conductance at the first location in the blood vessel;
measuring a first conductance value at the second location in the blood vessel; and
calculating the conductance at the second location in the blood vessel.
13. The method of claim 12 , wherein the step of determining a profile of the blood vessel comprises determining a profile of the blood vessel based on the conductance of the first location, the conductance of the second location, and the conductivities of the first and second solutions.
14. The method of claim 13 , wherein the profile of the blood vessel comprises cross-sectional areas of the plurality of locations.
15. The method of claim 13 , wherein:
the catheter further comprises a third electrode and a fourth electrode, each of the third and fourth electrodes having a proximal end and a distal end, the distal ends of the third and fourth electrodes located between the proximal and distal ends of the catheter, and the proximal ends of the third and fourth electrodes coupled with the processor;
the first and the third electrodes comprise excitation electrodes and the second and the fourth electrodes comprise detection electrodes; and
the distal ends of the second and fourth electrodes are located between the distal ends of the first and the third electrodes.
16. A kit for inserting at least one lead into a heart comprising:
a catheter having a proximal end and a distal end, the distal end of the catheter for placement into a blood vessel, the catheter comprising a first electrode and a second electrode, each of the first and second electrodes having a proximal end and a distal end, the distal ends of the first and second electrodes located between the proximal and distal ends of the catheter; and
at least one lead for placement in a targeted area, the lead having a proximal end and a distal end, and wherein the distal end of the lead may be removably coupled with the catheter;
wherein tie first and second electrodes of the catheter are capable of receiving data for determining a profile of a blood vessel and the first and second electrodes of the catheter are configured to be coupled with a processor for processing conductance data received from the catheter.
17. The kit of claim 16 , wherein the catheter further comprises a conductance wire.
18. The kit of claim 16 , wherein the catheter further comprises:
a third electrode and a fourth electrode, each of the third and fourth electrodes having a proximal end and a distal end, the distal ends of the third and fourth electrodes located between the proximal and distal ends of the catheter, and the proximal ends of the third and fourth electrodes coupled with the processor;
wherein the first and the third electrodes comprise excitation electrodes and the second and the fourth electrodes comprise detection electrodes and the distal ends of the second and fourth electrodes are located between the distal ends of the first and the third electrodes.
19. The kit of claim 16 , wherein:
the catheter further comprises a passageway for passing fluid through the catheter to the location of the distal ends of the first and second electrodes, such that fluid passing through the passageway comes in contact with the distal ends of the first and second electrodes; and
the catheter is capable of determining conductance data when the distal ends of the first and second electrodes are immersed in a first fluid and a second fluid.
20. The kit of claim 18 , wherein:
the catheter further comprises a passageway for passing fluid through the catheter to the location of the distal ends of the first and second electrodes, such that fluid passing through the passageway comes in contact with the distal ends of the first and second electrodes; and
the catheter is capable of determining conductance data when the distal ends of the first and second electrodes are immersed in a first fluid and a second fluid.
21. The kit of claim 19 , further comprising:
a syringe containing an amount of a first fluid; and
a syringe containing an amount of a second fluid.
22. A kit for inserting at least one lead into a heart, the kit comprising:
a catheter having a proximal end and a distal end, the distal end of the catheter for placement into a blood vessel, the catheter comprising:
a first electrode and a second electrode, each of the first and second electrodes having a proximal end and a distal end, the distal ends of the first and second electrodes located between the proximal and distal ends of the catheter;
a third electrode and a fourth electrode, each of the third and fourth electrodes having a proximal end and a distal end, the distal ends of the third and fourth electrodes located between the proximal and distal ends of the catheter;
at least one lead for placement in a targeted area, the lead having a proximal end and a distal end, and wherein the distal end of the lead may be removably coupled with the catheter; and
a passageway for passing fluid through the catheter to the location of the distal ends of the first and second electrodes, such that fluid passing through the passageway comes in contact with the distal ends of the first and second electrodes;
wherein the first and the third electrodes comprise excitation electrodes and the second and the fourth electrodes comprise detection electrodes and the distal ends of the second and fourth electrodes are located between the distal ends of the first and the third electrodes;
wherein the first and second electrodes of the catheter are capable of receiving data for determining a profile of a blood vessel and the first and second electrodes of the catheter are configured to be coupled with a processor for processing conductance data received from the catheter;
wherein and the proximal ends of the third and fourth electrodes coupled with the processor; and
wherein the catheter is capable of determining conductance data when the distal ends of the first and second electrodes are immersed in a first fluid and a second fluid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/503,646 US20100010503A1 (en) | 2007-01-23 | 2009-07-15 | Systems and methods for placing heart leads |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88184007P | 2007-01-23 | 2007-01-23 | |
PCT/US2008/000833 WO2008091609A2 (en) | 2007-01-23 | 2008-01-23 | Devices, systems, and methods for mapping organ profiles |
US52243209A | 2009-07-08 | 2009-07-08 | |
US12/503,646 US20100010503A1 (en) | 2007-01-23 | 2009-07-15 | Systems and methods for placing heart leads |
US12/503,341 US20100010368A1 (en) | 2007-01-23 | 2009-07-15 | Systems and methods for treating aortic lesions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/503,341 Continuation US20100010368A1 (en) | 2007-01-23 | 2009-07-15 | Systems and methods for treating aortic lesions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100010503A1 true US20100010503A1 (en) | 2010-01-14 |
Family
ID=39645061
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/522,432 Active 2025-06-02 US8632469B2 (en) | 2003-02-21 | 2008-01-23 | Devices, systems, and methods for mapping organ profiles |
US12/503,646 Abandoned US20100010503A1 (en) | 2007-01-23 | 2009-07-15 | Systems and methods for placing heart leads |
US12/503,341 Abandoned US20100010368A1 (en) | 2007-01-23 | 2009-07-15 | Systems and methods for treating aortic lesions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/522,432 Active 2025-06-02 US8632469B2 (en) | 2003-02-21 | 2008-01-23 | Devices, systems, and methods for mapping organ profiles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/503,341 Abandoned US20100010368A1 (en) | 2007-01-23 | 2009-07-15 | Systems and methods for treating aortic lesions |
Country Status (2)
Country | Link |
---|---|
US (3) | US8632469B2 (en) |
WO (1) | WO2008091609A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140200428A1 (en) * | 2003-02-21 | 2014-07-17 | 3Dt Holdings, Llc | Impedance devices and methods of using the same to obtain luminal organ measurements |
US20150126853A1 (en) * | 2013-10-22 | 2015-05-07 | 3Dt Holdings, Llc | Arterial system navigation methods and devices and systems to perform the same |
US9549679B2 (en) | 2012-05-14 | 2017-01-24 | Acist Medical Systems, Inc. | Multiple transducer delivery device and method |
US9854981B2 (en) | 2011-10-14 | 2018-01-02 | Acist Medical Systems, Inc. | Device and methods for measuring and treating an anatomical structure |
US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8078274B2 (en) | 2003-02-21 | 2011-12-13 | Dtherapeutics, Llc | Device, system and method for measuring cross-sectional areas in luminal organs |
US10034623B2 (en) | 2014-04-16 | 2018-07-31 | 3Dt Holdings, Llc | Devices, systems, and methods for determining vein geometric and compliance profiles for venous stenting |
US10413211B2 (en) * | 2003-02-21 | 2019-09-17 | 3Dt Holdings, Llc | Systems, devices, and methods for mapping organ profiles |
US10172538B2 (en) | 2003-02-21 | 2019-01-08 | 3Dt Holdings, Llc | Body lumen junction localization |
US8784336B2 (en) | 2005-08-24 | 2014-07-22 | C. R. Bard, Inc. | Stylet apparatuses and methods of manufacture |
US8209034B2 (en) * | 2008-12-18 | 2012-06-26 | Electrocore Llc | Methods and apparatus for electrical stimulation treatment using esophageal balloon and electrode |
US8388546B2 (en) | 2006-10-23 | 2013-03-05 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US7794407B2 (en) | 2006-10-23 | 2010-09-14 | Bard Access Systems, Inc. | Method of locating the tip of a central venous catheter |
US10751509B2 (en) | 2007-11-26 | 2020-08-25 | C. R. Bard, Inc. | Iconic representations for guidance of an indwelling medical device |
US10449330B2 (en) | 2007-11-26 | 2019-10-22 | C. R. Bard, Inc. | Magnetic element-equipped needle assemblies |
US10524691B2 (en) | 2007-11-26 | 2020-01-07 | C. R. Bard, Inc. | Needle assembly including an aligned magnetic element |
US8849382B2 (en) | 2007-11-26 | 2014-09-30 | C. R. Bard, Inc. | Apparatus and display methods relating to intravascular placement of a catheter |
US8781555B2 (en) | 2007-11-26 | 2014-07-15 | C. R. Bard, Inc. | System for placement of a catheter including a signal-generating stylet |
ES2832713T3 (en) | 2007-11-26 | 2021-06-11 | Bard Inc C R | Integrated system for intravascular catheter placement |
US9521961B2 (en) | 2007-11-26 | 2016-12-20 | C. R. Bard, Inc. | Systems and methods for guiding a medical instrument |
US9649048B2 (en) | 2007-11-26 | 2017-05-16 | C. R. Bard, Inc. | Systems and methods for breaching a sterile field for intravascular placement of a catheter |
US9901714B2 (en) | 2008-08-22 | 2018-02-27 | C. R. Bard, Inc. | Catheter assembly including ECG sensor and magnetic assemblies |
US8437833B2 (en) | 2008-10-07 | 2013-05-07 | Bard Access Systems, Inc. | Percutaneous magnetic gastrostomy |
US9532724B2 (en) | 2009-06-12 | 2017-01-03 | Bard Access Systems, Inc. | Apparatus and method for catheter navigation using endovascular energy mapping |
CN102802514B (en) | 2009-06-12 | 2015-12-02 | 巴德阿克塞斯系统股份有限公司 | Catheter tip positioning equipment |
US9445734B2 (en) | 2009-06-12 | 2016-09-20 | Bard Access Systems, Inc. | Devices and methods for endovascular electrography |
AU2010300677B2 (en) | 2009-09-29 | 2014-09-04 | C.R. Bard, Inc. | Stylets for use with apparatus for intravascular placement of a catheter |
CN102821679B (en) | 2010-02-02 | 2016-04-27 | C·R·巴德股份有限公司 | For the apparatus and method that catheter navigation and end are located |
EP2912999B1 (en) | 2010-05-28 | 2022-06-29 | C. R. Bard, Inc. | Apparatus for use with needle insertion guidance system |
EP4122385A1 (en) | 2010-05-28 | 2023-01-25 | C. R. Bard, Inc. | Insertion guidance system for needles and medical components |
CN102939051A (en) | 2010-06-13 | 2013-02-20 | 安吉奥梅特里克斯公司 | Methods and systems for determining vascular bodily lumen information and guiding medical devices |
KR101856267B1 (en) | 2010-08-20 | 2018-05-09 | 씨. 알. 바드, 인크. | Reconfirmation of ecg-assisted catheter tip placement |
WO2012058461A1 (en) * | 2010-10-29 | 2012-05-03 | C.R.Bard, Inc. | Bioimpedance-assisted placement of a medical device |
EP2729073A4 (en) | 2011-07-06 | 2015-03-11 | Bard Inc C R | Needle length determination and calibration for insertion guidance system |
US11759268B2 (en) | 2012-04-05 | 2023-09-19 | C. R. Bard, Inc. | Apparatus and methods relating to intravascular positioning of distal end of catheter |
EP2833786A4 (en) | 2012-04-05 | 2015-11-11 | Bard Access Systems Inc | Devices and systems for navigation and positioning a central venous catheter within a patient |
US10159531B2 (en) | 2012-04-05 | 2018-12-25 | C. R. Bard, Inc. | Apparatus and methods relating to intravascular positioning of distal end of catheter |
US9675257B2 (en) * | 2013-03-15 | 2017-06-13 | 3Dt Holdings, Llc | Impedance devices and methods to use the same to obtain luminal organ measurements |
WO2014150760A1 (en) * | 2013-03-15 | 2014-09-25 | Hattangadi, Neil | Perioperative feedback in endovascular aneurysm repair using physiological measurements |
WO2015017837A1 (en) * | 2013-08-01 | 2015-02-05 | The Regents Of The University Of California | Estimating gastroenterology tract parameters |
AU2014353891B2 (en) | 2013-11-22 | 2020-02-06 | Saluda Medical Pty Ltd | Method and device for detecting a neural response in a neural measurement |
EP3073910B1 (en) | 2014-02-06 | 2020-07-15 | C.R. Bard, Inc. | Systems for guidance and placement of an intravascular device |
US10973584B2 (en) | 2015-01-19 | 2021-04-13 | Bard Access Systems, Inc. | Device and method for vascular access |
WO2018031714A1 (en) | 2016-08-11 | 2018-02-15 | Foundry Innovation & Research 1, Ltd. | Systems and methods for patient fluid management |
SG11201706394QA (en) | 2015-02-12 | 2017-09-28 | Foundry Innovation & Res 1 Ltd | Implantable devices and related methods for heart failure monitoring |
US10349890B2 (en) | 2015-06-26 | 2019-07-16 | C. R. Bard, Inc. | Connector interface for ECG-based catheter positioning system |
EP3331426A1 (en) | 2015-08-03 | 2018-06-13 | Foundry Innovation&Research 1, Ltd. | Devices and methods for measurement of vena cava dimensions, pressure, and oxygen saturation |
US11000207B2 (en) | 2016-01-29 | 2021-05-11 | C. R. Bard, Inc. | Multiple coil system for tracking a medical device |
JP6824299B2 (en) | 2016-06-29 | 2021-02-03 | ピッコロ・メディカル,インコーポレーテッド | Equipment and methods for navigation, evaluation and / or diagnosis of blood vessels |
US11701018B2 (en) | 2016-08-11 | 2023-07-18 | Foundry Innovation & Research 1, Ltd. | Wireless resonant circuit and variable inductance vascular monitoring implants and anchoring structures therefore |
US11206992B2 (en) | 2016-08-11 | 2021-12-28 | Foundry Innovation & Research 1, Ltd. | Wireless resonant circuit and variable inductance vascular monitoring implants and anchoring structures therefore |
EP3705031A1 (en) | 2016-11-29 | 2020-09-09 | Foundry Innovation & Research 1, Ltd. | Wireless resonant circuit and variable inductance vascular implants for monitoring patient vasculature system |
US11944495B2 (en) | 2017-05-31 | 2024-04-02 | Foundry Innovation & Research 1, Ltd. | Implantable ultrasonic vascular sensor |
WO2018220146A1 (en) | 2017-05-31 | 2018-12-06 | Foundry Innovation & Research 1, Ltd. | Implantable sensors for vascular monitoring |
AU2018346252B2 (en) | 2017-10-03 | 2022-09-08 | Research Development Foundation | Systems and methods for coronary occlusion treatment |
EP3852622A1 (en) | 2018-10-16 | 2021-07-28 | Bard Access Systems, Inc. | Safety-equipped connection systems and methods thereof for establishing electrical connections |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4380237A (en) * | 1979-12-03 | 1983-04-19 | Massachusetts General Hospital | Apparatus for making cardiac output conductivity measurements |
US4840182A (en) * | 1988-04-04 | 1989-06-20 | Rhode Island Hospital | Conductance catheter |
US5522880A (en) * | 1990-06-11 | 1996-06-04 | Barone; Hector D. | Method for repairing an abdominal aortic aneurysm |
US5827192A (en) * | 1996-08-21 | 1998-10-27 | Cleveland Clinic Foundation | Method of determining the conductivity of blood |
US5842998A (en) * | 1996-08-21 | 1998-12-01 | Cleveland Clinic Foundation | Apparatus for determining the conductivity of blood |
US6231518B1 (en) * | 1998-05-26 | 2001-05-15 | Comedicus Incorporated | Intrapericardial electrophysiological procedures |
US20020165537A1 (en) * | 2000-03-31 | 2002-11-07 | Medtronic, Inc. | Method and system for delivering a medical electrical lead within a venous system |
US6514226B1 (en) * | 2000-02-10 | 2003-02-04 | Chf Solutions, Inc. | Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney |
US20040230131A1 (en) * | 2003-02-21 | 2004-11-18 | Kassab Ghassan S. | System and method for measuring cross-sectional areas and pressure gradients in luminal organs |
US20050256521A1 (en) * | 2002-03-15 | 2005-11-17 | Kozel Peter D | Method and apparatus for control of ablation energy and electrogram acquisition through multiple common electrodes in an electrophysiology catheter |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7727229B2 (en) * | 2001-05-01 | 2010-06-01 | C.R. Bard, Inc. | Method and apparatus for altering conduction properties in the heart and in adjacent vessels |
CA2421352A1 (en) * | 2002-03-08 | 2003-09-08 | Giovanni Battista Mancini (A.K.A. Mancini, G.B. John) | Vessel evaluation methods, apparatus, computer-readable media and signals |
US7769427B2 (en) * | 2002-07-16 | 2010-08-03 | Magnetics, Inc. | Apparatus and method for catheter guidance control and imaging |
EP1589872A4 (en) * | 2003-01-16 | 2009-05-06 | Galil Medical Ltd | Device, system, and method for detecting and localizing obstruction within a blood vessel |
US7654997B2 (en) * | 2004-04-21 | 2010-02-02 | Acclarent, Inc. | Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat |
EP1895927A4 (en) * | 2005-06-20 | 2011-03-09 | Medtronic Ablation Frontiers | Ablation catheter |
-
2008
- 2008-01-23 US US12/522,432 patent/US8632469B2/en active Active
- 2008-01-23 WO PCT/US2008/000833 patent/WO2008091609A2/en active Application Filing
-
2009
- 2009-07-15 US US12/503,646 patent/US20100010503A1/en not_active Abandoned
- 2009-07-15 US US12/503,341 patent/US20100010368A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4380237A (en) * | 1979-12-03 | 1983-04-19 | Massachusetts General Hospital | Apparatus for making cardiac output conductivity measurements |
US4840182A (en) * | 1988-04-04 | 1989-06-20 | Rhode Island Hospital | Conductance catheter |
US5522880A (en) * | 1990-06-11 | 1996-06-04 | Barone; Hector D. | Method for repairing an abdominal aortic aneurysm |
US5827192A (en) * | 1996-08-21 | 1998-10-27 | Cleveland Clinic Foundation | Method of determining the conductivity of blood |
US5842998A (en) * | 1996-08-21 | 1998-12-01 | Cleveland Clinic Foundation | Apparatus for determining the conductivity of blood |
US6231518B1 (en) * | 1998-05-26 | 2001-05-15 | Comedicus Incorporated | Intrapericardial electrophysiological procedures |
US6514226B1 (en) * | 2000-02-10 | 2003-02-04 | Chf Solutions, Inc. | Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney |
US20020165537A1 (en) * | 2000-03-31 | 2002-11-07 | Medtronic, Inc. | Method and system for delivering a medical electrical lead within a venous system |
US20050256521A1 (en) * | 2002-03-15 | 2005-11-17 | Kozel Peter D | Method and apparatus for control of ablation energy and electrogram acquisition through multiple common electrodes in an electrophysiology catheter |
US20040230131A1 (en) * | 2003-02-21 | 2004-11-18 | Kassab Ghassan S. | System and method for measuring cross-sectional areas and pressure gradients in luminal organs |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140200428A1 (en) * | 2003-02-21 | 2014-07-17 | 3Dt Holdings, Llc | Impedance devices and methods of using the same to obtain luminal organ measurements |
US9462960B2 (en) * | 2003-02-21 | 2016-10-11 | 3Dt Holdings, Llc | Impedance devices and methods of using the same to obtain luminal organ measurements |
US9854981B2 (en) | 2011-10-14 | 2018-01-02 | Acist Medical Systems, Inc. | Device and methods for measuring and treating an anatomical structure |
US9549679B2 (en) | 2012-05-14 | 2017-01-24 | Acist Medical Systems, Inc. | Multiple transducer delivery device and method |
US11109836B2 (en) | 2012-05-14 | 2021-09-07 | Acist Medical Systems, Inc. | Multiple transducer delivery device and method |
US20150126853A1 (en) * | 2013-10-22 | 2015-05-07 | 3Dt Holdings, Llc | Arterial system navigation methods and devices and systems to perform the same |
US11213281B2 (en) * | 2013-10-22 | 2022-01-04 | 3Dt Holdings, Llc | Arterial system navigation methods and devices and systems to perform the same |
US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
US11478215B2 (en) | 2015-06-15 | 2022-10-25 | The Research Foundation for the State University o | System and method for infrasonic cardiac monitoring |
Also Published As
Publication number | Publication date |
---|---|
WO2008091609A2 (en) | 2008-07-31 |
US20100010355A1 (en) | 2010-01-14 |
US20100010368A1 (en) | 2010-01-14 |
WO2008091609A3 (en) | 2008-11-06 |
US8632469B2 (en) | 2014-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230055624A1 (en) | Systems, Devices, And Methods For Mapping Organ Profiles | |
US11490829B2 (en) | Systems, devices, and methods for mapping organ profiles | |
US11510589B2 (en) | Body lumen junction localization | |
US8632469B2 (en) | Devices, systems, and methods for mapping organ profiles | |
US9974459B2 (en) | Localization of body lumen junctions | |
US20220054038A1 (en) | Impedance devices and methods of using the same to obtain luminal organ measurements | |
CA2516559C (en) | System and method for measuring cross-sectional areas and pressure gradients in luminal organs | |
US9675257B2 (en) | Impedance devices and methods to use the same to obtain luminal organ measurements | |
US8366707B2 (en) | Systems and methods for epicardial navigation | |
WO2011106715A1 (en) | Devices, systems, and methods for removing contrast from luminal organs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DTHERAPEUTICS, LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KASSAB, GHASSAN S.;REEL/FRAME:022961/0226 Effective date: 20070322 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |